Predictmedix (PMEDF) 20-F 15 Jun 22 2022 FY Annual report (foreign) Financial data

Document And Entity Information

Document And Entity Information	12 Months Ended
	Jan. 31, 2022shares
Entity Addresses [Line Items]
Entity Registrant Name	PREDICTMEDIX INC.
Entity Central Index Key	0001868079
Document Type	20-F
Document Period End Date	Jan. 31, 2022
Current Fiscal Year End Date	--01-31
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2022
Amendment Flag	false
Document Registration Statement	false
Document Annual Report	true
Document Transition Report	false
Document Shell Company Report	false
Entity File Number	000-00000
Entity Common Stock Shares Outstanding	109,051,292
Entity Incorporation, State or Country Code	Z4
Entity Address, Address Line One	77 King Street W.
Entity Address, Address Line Two	Suite 3000
Entity Address, City or Town	Toronto
Entity Address, Country	CA
Entity Address, Postal Zip Code	M5K 1G8
Entity Well Known Seasoned Issuer	No
Entity Current Reporting Status	Yes
Trading Symbol	PMED
Entity Interactive Data Current	No
Entity Filer Category	Non-accelerated Filer
Entity Voluntary Filers	No
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Document Accounting Standard	International Financial Reporting Standards
Title of 12(b) Security	Common
Auditor Name	Harbourside CPA
Auditor Location	Vancouver, Canada
Auditor Firm ID	6498
Canadian Securities Exchange [Member]
Entity Addresses [Line Items]
Security Exchange Name	NONE

Consolidated Statements of Fina

Consolidated Statements of Financial Position - CAD ($)	Jan. 31, 2022	Jan. 31, 2021
CURRENT
Cash and cash equivalents	$ 211,302	$ 480,051
Accounts receivable	169,545	0
Sales tax receivable	211,482	111,952
Prepaid expenses	49,295	155,442
Total current assets	641,624	747,445
Property and equipment	76,255	8,188
Intangible assets	518,778	248,010
TOTAL ASSETS	1,236,657	1,003,643
CURRENT
Accounts payable and accrued liabilities	334,452	135,354
Deferred revenue	15,220	0
TOTAL LIABILITIES	349,672	135,354
SHAREHOLDERS' EQUITY
Share Capital	5,716,131	4,031,650
Warrant reserve	510,483	115,802
Share-based payment reserve	675,560	853,848
Accumulated deficit	(6,015,189)	(4,133,011)
TOTAL SHAREHOLDERS' EQUITY	886,985	868,289
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	$ 1,236,657	$ 1,003,643

Consolidated Statements of Loss

Consolidated Statements of Loss and Comprehensive Loss - CAD ($)	12 Months Ended
	Jan. 31, 2022	Jan. 31, 2021
Profit or loss [abstract]
Revenue	$ 134,820	$ 0
Cost of revenue	50,000	0
Gross profit	84,820	0
Expenses
Administration and general	33,349	13,658
Amortization	79,288	3,509
Audit and accounting	33,983	38,560
Consulting fees	175,746	178,004
Investor relations	99,307	0
Legal fees	192,615	138,879
Management fees	269,845	217,050
Marketing expenses	508,609	221,670
Patent and trademark expenses	0	13,622
Payroll and related	165,342	0
Rent expense	32,147	21,500
Research and development	72,885	26,300
Share based compensation	182,996	946,361
Transfer agent and filing fees	51,244	57,908
Travel, entertainment and related	33,642	31,308
Vehicle use expenses	36,000	22,500
Total operating expenses	(1,966,998)	(1,930,829)
Income (loss) from discontinued operations	0	346,296
Loss and comprehensive loss	(1,882,178)	(1,584,533)
Loss and comprehensive loss attributable to:
Shareholders	(1,882,178)	(1,581,691)
Non-controlling interest	$ 0	$ (2,842)
Loss per share-Basic and Diluted	$ (0.017)	$ (0.016)
Weighted average number of shares outstanding-Basic and Diluted	107,925,066	101,195,130

Consolidated Statement Of Chang

Consolidated Statement Of Changes In Shareholders' Equity - CAD ($)	Share capital [Member]	Warrant reserve [Member]	Share-based payment reserve [Member]	Non-controlling interests [Member]	Deficit [Member]	Total
Beginning balance at Jan. 31, 2020	$ 4,119,484	$ 123,283	$ 15,922	$ (63,093)	$ (2,611,940)	$ 1,583,656
Beginning balance (Shares) at Jan. 31, 2020						104,054,149
Sale of Cultivar Jamaica	(540,000)			65,935	60,620	$ (413,445)
Sale of Cultivar Jamaica (Shares)						(4,000,000)
Share-based compensation			946,361			$ 946,361
Shares issued on acquisition of intangible asset	53,000					$ 53,000
Shares issued on acquisition of intangible asset (Shares)						50,000
Exercise of options	321,685		(108,435)			$ 213,250
Exercise of options (Shares)						1,455,000
Exercise of warrants	57,481	(7,481)				$ 50,000
Exercise of warrants (Shares)						100,000
Shares issued for consulting services	20,000					$ 20,000
Shares issued for consulting services (Shares)						58,824
Net loss for the year				$ (2,842)	(1,581,691)	$ (1,584,533)
Ending balance at Jan. 31, 2021	4,031,650	115,802	853,848		(4,133,011)	$ 868,289
Ending balance (Shares) at Jan. 31, 2021						101,717,973
Private placement of units	695,404	394,681				$ 1,090,085
Private placement of units (Shares)						3,114,569
Share-based compensation			182,996			$ 182,996
Share issuance costs	(3,770)					(3,770)
Exercise of options	956,597		(361,284)			$ 595,313
Exercise of options (Shares)						3,968,750
Shares issued for consulting services	36,250					$ 36,250
Shares issued for consulting services (Shares)						250,000
Net loss for the year					(1,882,178)	$ (1,882,178)
Ending balance at Jan. 31, 2022	$ 5,716,131	$ 510,483	$ 675,560		$ (6,015,189)	$ 886,985
Ending balance (Shares) at Jan. 31, 2022						109,051,292

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - CAD ($)	12 Months Ended
	Jan. 31, 2022	Jan. 31, 2021
OPERATING ACTIVITIES
Net loss	$ (1,882,178)	$ (1,584,533)
Non-cash items included in net loss and other adjustments:
Amortization	79,288	3,509
Loss (income) from discontinues operations	0	(346,296)
Share-based compensation	182,996	946,361
Shares issued for consulting services	36,250	8,333
Changes in non-cash working capital:
Sales tax receivable	(99,530)	(101,819)
Prepaid expenses	106,147	(44,965)
Accounts receivable	(169,545)	0
Accounts payable and accrued liabilities	199,098	68,837
Deferred revenue	15,220	0
Net assets from discontinued operations	0	(29,064)
CASH USED IN OPERATING ACTIVITIES	(1,532,254)	(1,079,637)
INVESTING ACTIVITIES
Purchase of property and equipment	(84,754)	0
Purchase of intangible assets	(333,369)	(195,010)
CASH USED IN INVESTING ACTIVITIES	(418,123)	(195,010)
FINANCING ACTIVITIES
Proceeds from issuance of units	1,090,085	0
Share issue expenses	(3,770)	0
Lease payments made for discontinued operations	0	(2,129)
Proceeds from exercise of warrants	0	50,000
Proceeds from exercise of options	595,313	213,250
CASH PROVIDED BY FINANCING ACTIVITIES	1,681,628	261,121
NET CHANGE IN CASH DURING THE PERIOD	(268,749)	(1,013,526)
CASH, BEGINNING OF PERIOD	480,051	1,493,577
CASH, END OF PERIOD	211,302	480,051
Cash paid for interest and income taxes	0	0
Non-cash transactions during the year affecting cash flows from financing and investing activities:
Shares issued for acquisition of intangible assets	0	53,000
Shares issued for prepayment and expense for consulting fees	$ 36,250	$ 20,000

Organization and Nature of Oper

Organization and Nature of Operations	12 Months Ended
	Jan. 31, 2022
Disclosure Of Organization And Nature Of Operations [Abstract]
Organization and Nature of Operations [Text Block]	1. Organization and Nature of Operations Admiral Bay Resources Inc. ("Admiral") was incorporated in British Columbia on September 3, 1987. Effective September 23, 2019, Admiral was part of a three-cornered amalgamation among Admiral, 2693980 Ontario Inc. (a wholly owned subsidiary of Admiral) and Cultivar Holdings Ltd. (the "Transaction"). Admiral completed the acquisition of all the issued and outstanding shares of Cultivar Holdings Ltd. by way of a three-cornered amalgamation, pursuant to which 2693980 Ontario Inc., amalgamated with Cultivar Holdings Ltd. Pursuant to the Transaction, each registered shareholder of Cultivar Holdings Ltd. received one (1) common share in the capital of the Admiral for each common share held, resulting in the issuance of an aggregate of 97,439,900 common shares to Cultivar Holdings Ltd. Shareholders. As part of the Transaction, warrants of Cultivar Holdings Ltd. were replaced with common share purchase warrants of Admiral. At completion of the Transaction, Admiral changed its name to Cultivar Holdings Inc. (the "Company"). On April 9, 2020, the Company announced that it has completed its name change from "Cultivar Holdings Inc." to "Predictmedix Inc." (the "Name Change"). The CUSIP number assigned to the Company's common shares following the name change is CUSIP 74040L100 (ISIN CA74040L1004). In connection with the Name Change, the Company's trading symbol, as listed on the CSE and the OTCQB have also been changed from "CULT" to "PMED", and from "CVRHF" to "PMEDF", respectively. On February 15, 2018, the Company had acquired a 49% interest in a newly incorporated Cultivar JA Limited, ("CJA") a corporation incorporated under the laws of Jamaica. The remaining 51% interest was owned by local Jamaican business partners. On March 27, 2020, the Company sold and discontinued its interests in CJA (Note 5). On July 16, 2018, the Company had acquired a 100% interest in a newly incorporated CannIP Holdings Inc. (formerly 2639745 Ontario Inc.) ("Cann") a corporation incorporated under the laws of the province of Ontario. Cann is engaged in the development of cosmetic and edible product lines, as well as investment in technology to detect an individual influence of cannabis. The Company did a one for one share exchange with Cann and issued 29,800,000 common shares to the shareholders of Cann. The Company, through its subsidiaries, is in the business of investment in technology to detect if an individual is under the influence of cannabis and to predict substance addiction. The Company is currently focusing on artificial intelligence ("AI") technologies which are targeting two specific areas: 1) workplace health and safety and 2) healthcare. The Company's corporate head office is located at 77 King Street W, Suite 3000, Toronto, Ontario, Canada, M5K 1G8.

Basis of Presentation and Going

Basis of Presentation and Going Concern	12 Months Ended
	Jan. 31, 2022
Disclosure Of Basis Of Presentation And Going Concern [Abstract]
Basis of Presentation and Going Concern [Text Block]	2. Basis of Presentation and Going Concern Basis of Preparation These consolidated financial statements have been prepared on the historical cost basis except for financial instruments recorded at fair value. In addition, these consolidated financial statements have been prepared using the accrual basis of accounting, except for cash flow information. The functional currency of the Company and its subsidiaries is the Canadian dollar, which is also the Company's reporting currency. Statement of Compliance The consolidated financial statements have been prepared in accordance with International Accounting Standards ("IAS") 1, "Presentation of Consolidated Financial Statements" using accounting policies consistent with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB") and interpretations issued by the International Financial Reporting Interpretations Committee ("IFRIC"). Basis of Consolidation These consolidated financial statements include the accounts of the Company and its subsidiaries; Cultivar Holdings Ltd. and Cann from the date of acquisition. The Company has a 100% interest in Cann and in Cultivar Holdings Ltd. The Company had a 49% interest in CJA which was sold on March 27, 2020 (see note 5). All inter-company transactions and balances have been eliminated on consolidation. Going Concern Assumption These consolidated financial statements have been prepared using IFRS on a going concern basis, which presumes the realization of assets and discharge of liabilities in the normal course of business, for the next fiscal year. At January 31, 2022, the Company had cash and cash equivalents of $211,302, working capital of $291,952 and an accumulated deficit of $6,015,189. The continuing operations of the Company are dependent on generation of revenues and profits and funding to be provided by equity investors. The Company intends to finance its future requirements through a combination of equity and/or debt issuance. There is no assurance that the Company will be able to obtain such financings or obtain them on favorable terms. This uncertainty may cast significant doubt about the ability of the Company to continue as a going concern. These consolidated financial statements do not include any adjustments to the carrying value or presentation of assets or liabilities that might be necessary should the Company be unable to continue as a going concern. These adjustments could be material. Significant Accounting Judgments and Estimates The preparation of these consolidated financial statements in compliance with IFRS requires management to make certain critical accounting estimates and assumptions. These estimates and assumptions affect the reported amounts of assets, liabilities, shareholders' equity, and the disclosure of contingent assets and liabilities, as at the date of the financial statements, and expenses for the years reported. Critical Judgements The preparation of these consolidated financial statements requires management to make judgements regarding the going concern of the Company (discussed above), as well as the determination of functional currency. The functional currency is the currency of the primary economic environment in which an entity operates and has been determined for each entity within the Company. The functional currency for the Company and its subsidiaries has been determined to be the Canadian dollar. Key Sources of Estimation Uncertainty Because a precise determination of many assets and liabilities is dependent upon future events, the preparation of financial statements in conformity with IFRS requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. Actual results could differ from those estimates and such differences could be significant. Significant estimates made by management affecting the consolidated financial statements include: Share-based payments Estimating fair value for granted stock options requires determining the most appropriate valuation model which is dependent on the terms and conditions of the grant. This estimate also requires determining the most appropriate inputs to the valuation model including the expected life of the option, volatility, dividend yield, and rate of forfeitures and making assumptions about them. Deferred tax assets & liabilities The estimation of income taxes includes evaluating the recoverability of deferred tax assets and liabilities based on an assessment of the Company's ability to utilize the underlying future tax deductions against future taxable income prior to expiry of those deductions. Management assesses whether it is probable that some or all of the deferred income tax assets and liabilities will not be realized. The ultimate realization of deferred tax assets and liabilities is dependent upon the generation of future taxable income, which in turn is dependent upon the successful discovery, extraction, development and commercialization of mineral reserves. To the extent that management's assessment of the Company's ability to utilize future tax deductions changes, the Company would be required to recognize more or fewer deferred tax assets or liabilities, and deferred income tax provisions or recoveries could be affected. Key Sources of Estimation Uncertainty (Cont'd) Useful life of property and equipment Property and equipment is depreciated over its estimated useful life. Estimated useful lives are determined based on current facts and past experience and takes into consideration the anticipated physical life of the asset, the potential for technological obsolescence, and regulations. Useful life of intangible assets The intangible asset is depreciated over its estimated useful life. Estimated useful lives are determined based on current facts and past experience and takes into consideration the anticipated life of the asset, the potential for technological obsolescence, and regulations. COVID-19 Estimation Uncertainty In March 2020, the World Health Organization declared coronavirus COVID-19 a global pandemic. This contagious disease outbreak, which has continued to spread, and any related adverse public health developments, has adversely affected workforces, economies, and financial markets globally, potentially leading to an economic downturn. It is not possible for the Company to predict the duration or magnitude of the adverse results of the outbreak and its effects on the Company's business or ability to raise funds. Approval of the consolidated financial statements These consolidated financial statements were authorized for issuance by the Board of Directors on May 31, 2022.

Significant Accounting Policies

Significant Accounting Policies	12 Months Ended
	Jan. 31, 2022
Disclosure Of Significant Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	3. Significant Accounting Policies The accounting policies set out below have been applied consistently to all periods presented in these consolidated financial statements. Cash Cash comprises of cash held at banks and amounts held in trust. The majority of the Company's cash is held in a major financial institution. The Company does not invest in any asset-backed deposits or investments. Income taxes Income tax on profit or loss for the period comprises of current and deferred tax. Current tax is the expected tax paid or payable on the taxable income for the period, using tax rates enacted or substantively enacted at the statement of financial position date, and any adjustment to tax paid or payable in respect of previous periods. Deferred tax is recorded by providing for temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. A deferred tax asset is recognized only to the extent that it is probable that future taxable profits will be available against which the asset can be utilized. Deferred tax assets are reduced to the extent that it is no longer probable that the related tax benefit will be realized. The effect on deferred tax assets and liabilities of a change in income tax rates is recognized in the period that includes the date of the enactment or substantive enactment of the change. Deferred tax assets and liabilities are presented separately except where there is a right of set-off within fiscal jurisdictions Foreign currency translation Foreign currency transactions are translated into Canadian dollars as follows: At the transaction date, each asset, liability, revenue and expense denominated in a foreign currency is translated into Canadian dollars by the use of the exchange rate in effect at that date. At the period-end date, unsettled monetary assets and liabilities are translated into Canadian dollars by using the exchange rate in effect at the year-end date and the related translation differences are recognized in net loss. Non-monetary assets and liabilities that are measured at historical cost are translated into Canadian dollars by using the exchange rate in effect at the date of the initial transaction and are not subsequently restated. Non-monetary assets and liabilities that are measured at fair value or a revalued amount are translated into Canadian dollars by using the exchange rate in effect at the date the value is determined, and the related translation differences are recognized in net loss or other comprehensive loss consistent with where the gain or loss on the underlying non-monetary asset or liability has been recognized. Share Capital Common shares and warrants are classified as shareholders' equity. Incremental costs directly attributable to the issue of common shares are recognized as a reduction of shareholders' equity, net of tax. The Company has adopted a relative fair value method with respect to the measurement of common shares and warrants issued as private placement units. The relative fair value method allocates value to each component on a pro-rata basis, based on the fair value of the components calculated independently of one another. The Company considers the market value of the common shares issued as fair value and measures the fair value of the warrant component of the unit using the Black-Scholes option pricing model. The unit value is then allocated, pro-rata, between the two components, with fair value attributed to the warrants being recorded to the Company's warrant reserve. Loss per share Loss per share is computed by dividing the net loss applicable to common shares of the Company by the weighted average number of common shares outstanding for the relevant period. Diluted loss per common share is computed by dividing the net loss applicable to common shares by the sum of the weighted average number of common shares issued and outstanding and all additional common shares that would have been outstanding, if potentially dilutive instruments were converted. Share-based payments The Company grants stock options to buy common shares of the Company to consultants and service providers. The Company recognizes share-based compensation expense based on the estimated fair value of the options. A fair value measurement is made for each vesting instalment within each option grant and is determined using the Black-Scholes option-pricing model. The fair value of the options is recognized over the vesting period of the options granted as both share-based compensation expense and reserves. This includes a forfeiture estimate, which is revised for actual forfeitures in subsequent periods. The reserves account is subsequently reduced if the options are exercised, and the amount initially recorded is then credited to capital stock. In situations where equity instruments are issued to non-employees and some or all of the goods or services received by the entity as consideration cannot be specifically identified, they are measured at the fair value of the share-based payment. Otherwise, share-based payments are measured at the fair value of the goods or services received. Property and equipment Property and equipment is carried at cost, less accumulated amortization and accumulated impairment losses. The cost of the item of property and equipment consists of the purchase price, and any costs directly attributable to bringing the asset to the location and condition necessary for its intended use. An item of property and equipment is derecognized upon disposal or when no future economic benefits are expected to arise from the continued use of the asset. Any gain or loss arising on disposal of the asset, determined as the difference between the net disposal proceeds and the carrying amount of the asset, is recognized in the consolidated statement of loss and comprehensive loss. The cost of repairs and maintenance is expensed as incurred. The Company amortizes its property and equipment using the following rates: Equipment 30% per annum, declining balance Intangible assets Intangible assets are measured at cost less accumulated amortization and accumulated impairment losses. Amortization is recorded on a straight-line basis over the estimated useful life of the asset acquired, which varies depending on the nature of the intangible asset. Intangible assets are amortized from the date when they are available for use. The estimated useful life is reviewed at the end of each reporting period with the effect of any changes in estimate being accounted for on a prospective basis. Internally incurred development costs are recognized as intangible assets when the following criteria are met: a) b) c) d) e) f) Intangible assets may relate to the Company's external development expenditures in relation to intellectual property development. Development expenditures that do not meet these criteria are recognized as an expense as incurred. Intangible assets with definite lives are assessed for impairment whenever there is an indication that the intangible asset may be impaired. These intangible assets will be amortized when they are ready for use. The amortization period and the amortization method are reviewed at the end of each reporting period. Changes in the expected useful life or the expected pattern of consumption of future economic benefits embodied in the asset are accounted for by changing the amortization period or method, as appropriate, and are treated as changes in accounting estimates on a prospective basis. Impairment The carrying amount of the Company's assets is reviewed for an indication of impairment at the end of each reporting period. If an indication of impairment exists, the Company makes an estimate of the asset's recoverable amount. Individual assets are grouped for impairment assessment purposes at the lowest level at which there are identifiable cash flows that are largely independent of the cash flows of other groups of assets. Recoverable amount of an asset group is the higher of its fair value less costs to sell and its value in use. In assessing value in use, the estimated future cash flows are adjusted for the risks specific to the asset group and are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money. Where the carrying amount of an asset group exceeds its recoverable amount, the asset group is considered impaired and is written down to its recoverable amount. Impairment losses are recognized in profit or loss. An assessment is made at each reporting date as to whether there is any indication that previously recognized impairment losses may no longer exist or may have decreased. If such indication exists, the recoverable amount is estimated. A previously recognized impairment loss is reversed only if there has been a change in the estimates used to determine the asset's recoverable amount. An impairment loss is reversed only to the extent that the asset's carrying amount does not exceed the carrying amount that would have been determined, net of depreciation, if no impairment loss had been recognized. Financial Instruments Financial assets and financial liabilities are recognized on the consolidated statements of financial position when the Company becomes a party to the contractual provisions of the financial instrument. The following is the Company's accounting policy for financial instruments under IFRS 9: Classification The Company classifies its financial instruments in the following categories: at fair value through profit and loss ("FVTPL"), at fair value through other comprehensive income (loss) ("FVTOCI") or at amortized cost. The Company determines the classification of financial assets at initial recognition. The classification of debt instruments is driven by the Company's business model for managing the financial assets and their contractual cash flow characteristics. Equity instruments that are held for trading are classified as FVTPL. For other equity instruments, on the day of acquisition the Company can make an irrevocable election (on an instrument-by-instrument basis) to designate them as at FVTOCI. Financial liabilities are measured at amortized cost, unless they are required to be measured at FVTPL (such as instruments held for trading or derivatives) or if the Company has opted to measure them at FVTPL. Measurement Financial assets and liabilities at amortized cost Financial assets and liabilities at amortized cost are initially recognized at fair value plus or minus transaction costs, respectively, and subsequently carried at amortized cost less any impairment. Financial assets and liabilities at FVTPL Financial assets and liabilities carried at FVTPL are initially recorded at fair value and transaction costs are expensed in the consolidated statements of loss and comprehensive loss. Realized and unrealized gains and losses arising from changes in the fair value of the financial assets and liabilities held at FVTPL are included in the consolidated statements of loss and comprehensive loss in the period in which they arise. Debt investments at FVOCI These assets are subsequently measured at fair value. Interest income calculated using the effective interest method, foreign exchange gains and losses and impairment are recognized in profit or loss. Other net gains and losses are recognized in OCI. On derecognition, gains and losses accumulated in OCI are reclassified to profit or loss. Equity investments at FVOCI These assets are subsequently measured at fair value. Dividends are recognized as income in profit or loss unless the dividend clearly represents a recovery of part of the cost of the investment. Other net gains and losses are recognized in OCI and are never reclassified to profit or loss. Impairment of financial assets at amortized cost The Company recognizes a loss allowance for expected credit losses on financial assets that are measured at amortized cost. At each reporting date, the Company measures the loss allowance for the financial asset at an amount equal to the lifetime expected credit losses if the credit risk on the financial asset has increased significantly since initial recognition. If at the reporting date, the financial asset has not increased significantly since initial recognition, the Company measures the loss allowance for the financial asset at an amount equal to the twelve month expected credit losses. The Company shall recognize in the consolidated statements of loss and comprehensive loss, as an impairment gain or loss, the amount of expected credit losses (or reversal) that is required to adjust the loss allowance at the reporting date to the amount that is required to be recognized. Derecognition Financial assets The Company derecognizes financial assets only when the contractual rights to cash flows from the financial assets expire, or when it transfers the financial assets and substantially all of the associated risks and rewards of ownership to another entity. Financial liabilities The Company derecognizes a financial liability when its contractual obligations are discharged or cancelled or expired. The Company also derecognizes a financial liability when the terms of the liability are modified such that the terms and / or cash flows of the modified instrument are substantially different, in which case a new financial liability based on the modified terms is recognized at fair value. Gains and losses on derecognition are generally recognized in profit or loss. The Company's financial assets and liabilities are classified as follows: Asset or Liability Classification Cash FVTPL Accounts receivable Amortized cost Accounts payable Amortized cost The Company determines the fair value of financial instruments according to the following hierarchy based on the amount of observable inputs used to value the instrument. Level 1 – Quoted prices are available in active markets for identical assets or liabilities as of the reporting date. Active markets are those in which transactions occur in sufficient frequency and volume to provide pricing information on an ongoing basis. Level 2 – Pricing inputs are other than quoted prices in active markets included in Level 1. Prices in Level 2 are either directly or indirectly observable as of the reporting date. Level 2 valuations are based on inputs, including quoted forward prices for commodities, time value and volatility factors, which can be substantially observed or corroborated in the marketplace. Level 3 – Valuations in this level are those with inputs for the asset or liability that are not based on observable market data. Cash has been measured at fair value using Level 1 inputs. Impairment of financial assets Financial assets are assessed at each reporting date to determine whether there is objective evidence that they are impaired. A financial asset is impaired if objective evidence indicates that a loss event has occurred after the initial recognition of the asset and that the loss event had a negative effect on the estimated future cash flows of that asset that can be estimated reliably. An impairment loss in respect of a financial asset measured at amortized cost is calculated as the difference between its carrying amount and the present value of the estimated future cash flows discounted at the asset's original effective interest rate. Losses are recognized in profit or loss and reflected in a separate line item. When a subsequent event causes the amount of impairment loss to decrease, the decrease in impairment loss is reversed through profit or loss. Revenue recognition Revenue is recognized at an amount that reflects the expected consideration receivable in exchange for transferring goods or services to a customer, applying the following five steps: 1. 2. 3. 4. 5. Under IFRS 15, the Company classified its revenue as being principally derived from the following source: Screening services revenue on deployment of safe entry stations for use of the Company's technology. Revenue from the sale of screening services is recognized based on the transaction price. Upfront fees as set-up fees are included in the transaction price and allocated to the performance obligation in the contract. Revenue is recognized as the performance obligations are satisfied. New standards not yet adopted Classification of Liabilities as Current or Non-Current (Amendments to IAS 1) The IASB has published Classification of Liabilities as Current or Non-Current (Amendments to IAS 1) which clarifies the guidance on whether a liability should be classified as either current or non-current. The amendment a) clarify that the classification of liabilities as current or non-current should only be based on rights that are in place "at the end of the reporting period" b) clarify that classification is unaffected by expectations about whether an entity will exercise its right to defer settlement of a liability, and c) make clear that settlement includes transfers to the counterparty of cash, equity instruments, other assets or services that result in extinguishment of the liability. This amendment is effective for annual periods beginning on or after January 1, 2022. Earlier application is permitted. The extent of the impact of adoption of this amendment has not yet been determined.

Acquisitions

Acquisitions	12 Months Ended
	Jan. 31, 2022
Disclosure of detailed information about business combination [abstract]
Acquisitions [Text Block]	4. Acquisitions During the year ended January 31, 2020, the Company completed the following acquisition: Effective September 23, 2019, the Company was part of a three-cornered amalgamation among the Company, 2693980 Ontario Inc. (a wholly owned subsidiary) and Cultivar Holdings Ltd. (the "Transaction"). The result of the transaction was that Admiral acquired all the issued and outstanding securities of Cultivar Holdings Ltd. on the basis of one share of Admiral for each share of former Cultivar. All outstanding warrants to purchase former Cultivar shares were exchanged, on an equivalent basis, for warrants to purchase shares of the Company. At completion of the transaction, Admiral changed its name to Cultivar Holdings Inc. and former Cultivar was amalgamated into 2693980 Ontario Inc. Under IFRS, this was considered a Reverse Merger and Recapitalization (commonly referred to as a Reverse Take Over or "RTO"). The Company issued 6,514,249 shares valued at $0.21 per share, with a total value of $1,367,992 for the acquisition. The fair value of the acquired assets and liabilities assumed is as follows: Assets acquired by the Company: Cash $ 3,448 Prepaid expenses 1,125 Liabilities assumed by the Company: Accounts payable and accrued liabilities (19,127 ) Loans payable (107,525 ) Net liabilities assumed (122,079 ) Fair value of shares issued (1,367,992 ) Loss on acquisition $ (1,490,071 )

Sale of interest in Cultivar JA

Sale of interest in Cultivar JA Limited	12 Months Ended
	Jan. 31, 2022
Disclosure Of Sale Of Interest In Cultivar Ja Limited [Abstract]
Sale of interest in Cultivar JA Limited [Text Block]	5. On March 27, 2020, the Company entered into a sale agreement (the "Sale Agreement") with respect to its 49% interest in Cultivar JA Limited ("Cultivar JA"), which holds a provisional cannabis cultivation license in Jamaica. Pursuant to the terms of the Sale Agreement, the Company's wholly-owned subsidiary, Cultivar Holdings Ltd., agreed to sell its 49% interest in Cultivar JA and all related royalty interests to the principals of Cultivar JA in exchange for the principals of Cultivar JA agreeing to return and cancel 4,000,000 common shares of the Company owned by the principals. In addition, the principals also agreed to terminate their right to receive an additional 500,000 common shares of the Company which had been reserved for issuance upon Jamaica's Licensing Authority issuing final approval for Cultivar JA's license. The sale agreement constituted a discontinued operation involving the loss of control of Cultivar JA by the Company. A discontinued operation is a component of the Company's business that represents a separate major line of business or a geographical area of operations that has been disposed of or is held for sale. Classification as a discontinued operation occurs upon disposal or earlier if the operation meets the criteria to be classified as held for sale. When an operation is classified as a discontinued operation the comparative statement of comprehensive loss and cash flow operation is re-presented as if the operation had been discontinued from the start of the comparative period. The sale agreement constituted a discontinued operation of the Company effective March 27, 2020. As a result, all the assets and liabilities of Cultivar JA have been removed from the statement of financial position of the Company. The cancellation of 4,000,000 shares of the Company have been valued at $540,000, being the fair value of the shares on the date of the sale transaction. The expenses of Cultivar JA have been determined to be a discontinued operation by the Company, and as a result, have been disclosed separately on the statement of income (loss) and comprehensive income (loss) For the For the Expenses: Amortization $ - $ 2,871 Interest expense - 687 Travel, entertainment and related - 2,014 Net loss for the period prior to the sale transaction - (5,572 ) Gain on divestiture - 351,868 Income (loss) from discontinued operations, net of tax $ - $ 346,296

Prepaid Expenses

Prepaid Expenses	12 Months Ended
	Jan. 31, 2022
Disclosure Of Prepaid Expenses [Abstract]
Prepaid Expenses [Text Block]	6. Prepaid Expenses Prepaid expenses as of January 31, 2022 include $nil (2021: $70,060) to conduct a study to further validate its proprietary impairment detection technology for both alcohol and cannabis.

Property and Equipment

Property and Equipment	12 Months Ended
	Jan. 31, 2022
Property, plant and equipment [abstract]
Property and Equipment [Text Block]	7. Property and Equipment Equipment Leasehold Improvement Total Cost Balance as at January 31, 2020 $ 21,953 $ 9,916 $ 31,869 Discontinuance of business (Note 5) (8,585 ) (9,916 ) (18,501 ) Balance as at January 31, 2021 $ 13,368 $ - $ 13,368 Additions 84,755 - 84,755 Balance as at January 31, 2022 $ 98,123 $ - $ 98,123 Accumulated Amortization Balance as at January 31, 2020 $ 5,749 $ 5,929 $ 11,678 Amortization 3,509 - 3,509 Discontinuance of business (Note 5) (4,078 ) (5,929 ) (10,007 ) Balance as at January 31, 2021 $ 5,180 $ - $ 5,180 Amortization 16,688 - 16,688 Balance as at January 31, 2022 $ 21,868 $ - $ 21,868 Net Carrying Amounts As at January 31, 2022 $ 76,255 $ - $ 76,255 As at January 31, 2021 $ 8,188 $ - $ 8,188

Intangible Assets

Intangible Assets	12 Months Ended
	Jan. 31, 2022
Disclosure of detailed information about intangible assets [abstract]
Intangible Assets [Text Block]	8. Intangible Assets a) On July 21, 2020, the Company completed the acquisition of MobileWellbeing ("MWB"), an innovative, feature rich, Telemedicine Remote Patient Monitoring platform that will integrate with the Company's Artificial Intelligence ("AI") driven rapid screening system for infectious diseases, including COVID-19. The consideration for the purchase was satisfied by payment in cash for $25,000, issuance of 20,000 shares and additional 30,000 shares to be issued on the 90 th The acquisition has contingent considerations and royalty payments on achievement of certain milestones. The Company shall pay royalty of 20 percent of gross sales from the first $2.5 million in sales generated exclusively from the MWB platform. In addition, the Company is obligated to issue an additional 200,000 common shares commencing with the release of the initial version of the MWB platforms to the market and achievement of sales related milestones. Contingent consideration in an asset acquisition was discussed at the March 2016 IFRS Interpretations Committee (IFRIC) meeting. An accounting policy choice exists, therefore an entity may recognize a liability for the expected variable payments at the time control of the underlying asset is obtained or they may only recognize such a liability as the related activity that gives rise to the variability occurs. The Company has opted to recognize the liability only when the related activity that gives rise to the variability occurs. Consideration Cash consideration on closing $ 25,000 Issued shares (50,000 shares issued at $1.06/share) 53,000 $ 78,000 Purchase Price allocation Intangible asset- MWB remote patient monitoring platform $ 78,000 $ 78,000 b) infectious disease symptom screening solution ("IDSS") The Company has commenced amortization on the intangible assets on a straight line basis over the useful life estimated to be for 5 years. The Company's intangible assets are comprised of the following: MWB IDSS Total Cost Balance at January 31, 2020 $ - $ - $ - Acquisition 78,000 - 78,000 Additions 13,970 156,040 170,010 Balance at January 31, 2021 $ 91,970 $ 156,040 $ 248,010 Additions 46,591 286,778 333,369 Balance at January 31, 2022 $ 138,561 $ 442,818 $ 581,379 Accumulated amortization: Balance as at January 1, 2020 $ - $ - $ - Amortization - - - Balance as at January 31, 2021 $ - $ - $ - Amortization 18,990 43,611 62,601 Balance as at January 31, 2022 $ 18,990 $ 43,611 $ 62,601 Net Book Value Balance, January 31, 2021 $ 91,970 $ 156,040 $ 248,010 Balance, January 31, 2022 $ 119,571 $ 399,207 $ 518,778

Leases

Leases	12 Months Ended
	Jan. 31, 2022
Lease liabilities [abstract]
Leases [Text Block]	9. Right-of-use assets of $nil (January 31, 2021- $nil) and total lease liability of $nil (January 31, 2021- $nil) have been removed from the statement of financial position of the Company as of January 31, 2021 on account of the sale of Company's interest in Cultivar JA (Note 5). Right of use assets The Company's right of use assets as at January 31, 2022 and 2021 were as follows: Balance as at January 31, 2020 $ 12,192 Amortization (2,871 ) Discontinuance of business (Note 5) (9,321 ) As at January 31, 2022 and 2021 $ - Lease liability At the commencement date of the leases, the lease liability was measured at the present value of the lease payments that were not paid at that date. The lease payments are discounted using an interest rate of 18% which is the Company's incremental borrowing rate. Lease liability interest expense recognized in profit and loss and lease payments recognized in the financing component of statement of cash flows are as follows: Balance as at January 31, 2020 $ 15,189 Interest expense 687 Lease payments made during the year (2,129 ) Discontinuance of business (Note 5) (13,747 ) As at January 31, 2022 and 2021 $ - The Company's lease liability as at January 31, 2022 and 2021 was as follows: January 31, 2022 January 31, 2021 Lease liability - current $ - $ - Lease liability - non- current - Total lease liability $ - $ -

Stock-based Compensation

Stock-based Compensation	12 Months Ended
	Jan. 31, 2022
Disclosure Of Share Based Compensation [Abstract]
Stock-based compensation [Text Block]	10. Stock-based Compensation The Company has established a stock option plan whereby officers, directors, employees and service providers may be granted options to purchase common shares at a fixed price. Vesting and expiry provisions are determined at the date of grant. The plan provides for the issuance of stock options to acquire up to 10% of the Company's issued and outstanding capital. The plan is a rolling plan as the number of shares reserved for issuance pursuant to the grant of stock options will increase as the Company's issued and outstanding share capital increases. Year ended January 31, 2021 a) In October 2018, the Company granted options to a consultant to acquire a total of 250,000 common shares. These options were issued at an exercise price of $0.10 per share and vested 75,000 immediately, 37,500 at the date of engineering milestone (vested during the quarter ended July 31, 2019) and balance 137,500 on completion of additional milestones, including 75,000 on model development (vested during the quarter ended October 31, 2019) and 62,500 on project handover with an expiry term of two years. These options expired unexercised in October 2020. The fair value of each option used for the purpose of estimating the stock-based compensation was estimated using the Black-Scholes option pricing model with the following assumptions: Risk free rate 2.26% Expected dividends 0% Expected forfeiture rate 0% Expected volatility 100% Expected life 2 years Unvested stock-based compensation expense as of January 31, 2021 $ - During the year ended January 31, 2021, the Company expensed $3,311, resulting in unvested stock-based compensation expense of $nil as of January 31, 2021. b) In November 2018, the Company granted options to a consultant to acquire a total of 100,000 common shares. These options were issued at an exercise price of $0.10 per share and vested 25,000 immediately, and 25,000 each on April 1, 2019, September 1, 2019 and March 1, 2020 with an expiry term of three years. The fair value of each option used for the purpose of estimating the stock-based compensation is estimated using the Black-Scholes option pricing model with the following assumptions: Risk free rate 2.30% Expected dividends 0% Expected forfeiture rate 0% Expected volatility 100% Expected life 3 years Unvested stock-based compensation expense as of January 31, 2021 $ - During the year ended January 31, 2021, the Company expensed $260, resulting in unvested stock-based compensation expense of $nil as of January 31, 2021. c) On April 6, 2020, the Company granted options to its directors, officers and consultants to purchase up to 9,850,000 common shares. These options were issued at an exercise price of $0.15 per share and have varying vesting periods, with the majority being in equal installments over a quarterly basis throughout the term. These options have a term of one (1) year expiring on April 6, 2021. The fair value of each option used for the purpose of estimating the stock-based compensation is estimated using the Black-Scholes option pricing model with the following assumptions: Risk free rate 0.47% Expected dividends 0% Expected forfeiture rate 0% Expected volatility 135% Expected life 1 year Unvested stock-based compensation expense as of January 31, 2021 $ - During the year ended January 31, 2021, the Company expensed $742,833 relating to the vesting of options, resulting in unvested stock-based compensation expense of $nil as of January 31, 2021. d) On July 17, 2020, the Company granted options to a consultant to purchase up to 80,000 common shares. These options were issued at an exercise price of $1.02 per share and vest one year after date of grant. These options have a term of five (5) years expiring on July 17, 2025. The fair value of each option used for the purpose of estimating the stock-based compensation is estimated using the Black-Scholes option pricing model with the following assumptions: Risk free rate 0.35% Expected dividends 0% Expected forfeiture rate 0% Expected volatility 207% Expected life 5 years Unvested stock-based compensation expense as of January 31, 2021 $ 34,246 During the year ended January 31, 2021, the Company expensed $40,603 relating to the vesting of options, resulting in unvested stock- based compensation expense of $34,246 as of January 31, 2021. e) On September 10, 2020, the Company granted options to a consultant to purchase up to 70,000 common shares. These options were issued at an exercise price of $0.54 per share and vest on completion of milestones, including 40,000 upon approval of a McGill University study and 30,000 upon completion of the study. The Company did not record any stock-based compensation on these options, as they have not yet vested as at January 31, 2021. f) On September 17, 2020, the Company granted options to a consultant to purchase up to 200,000 common shares. These options were issued at an exercise price of $0.54 per share and vest on date of grant. These options expire on March 30, 2022. The fair value of each option used for the purpose of estimating the stock-based compensation is estimated using the Black-Scholes option pricing model with the following assumptions: Risk free rate 0.26% Expected dividends 0% Expected forfeiture rate 0% Expected volatility 189% Expected life 1.5 years Unvested stock-based compensation expense as of January 31, 2021 $ - During the year ended January 31, 2021, the Company expensed $81,979, relating to the vesting of options, resulting in unvested stock- based compensation expense of $nil as of January 31, 2021. g) On September 21, 2020, the Company granted options to a consultant to purchase up to 250,000 common shares. These options were issued at an exercise price of $0.59 per share and vest in equal installments over a quarterly basis throughout the term. These options have a term of one (1) year expiring on September 21, 2021. The fair value of each option used for the purpose of estimating the stock-based compensation is estimated using the Black-Scholes option pricing model with the following assumptions: Risk free rate 0.23% Expected dividends 0% Expected forfeiture rate 0% Expected volatility 188% Expected life 1 year Unvested stock-based compensation expense as of January 31, 2021 $ 18,958 During the year ended January 31, 2021, the Company expensed $77,375 relating to the vesting of options, resulting in unvested stock- based compensation expense of $18,958 as of January 31, 2021. As of January 31, 2021, there was $53,204 of unvested stock-based compensation expense. Year ended January 31, 2022 (a) (b) (c) Risk free rate 0.26% Expected dividends 0% Expected forfeiture rate 0% Expected volatility 134.3% Expected life 1 year Unvested stock-based compensation expense as of January 31, 2022 $ 1,834 During the year ended January 31, 2022, the Company expensed $50,675 relating to the vesting of options, resulting in unvested stock- based compensation expense of $1,834 as of January 31, 2022. (d) Risk free rate 0.32% Expected dividends 0% Expected forfeiture rate 0% Expected volatility 146.38% Expected life 1.5 years Unvested stock-based compensation expense as of January 31, 2022 $ 6,778 During the year ended January 31, 2022, the Company expensed $48,672 relating to the vesting of options, resulting in unvested stock- based compensation expense of $6,778 as of January 31, 2022. Year ended January 31, 2022 (e) Risk free rate 0.38% Expected dividends 0% Expected forfeiture rate 0% Expected volatility 131.33% Expected life 1.5 years Unvested stock-based compensation expense as of January 31, 2022 $ 7,826 During the year ended January 31, 2022, the Company expensed $30,445 relating to the vesting of options, resulting in unvested stock- based compensation expense of $7,826 as of January 31, 2022. As of January 31, 2022, there was a total of $16,438 of unvested stock-based compensation expense. Continuity of the Company's options is as follows: Number of Weighted Average Outstanding, January 31, 2020 350,000 $ 0.10 Granted 10,450,000 $ 0.18 Expired (250,000 ) $ 0.10 Exercised (1,455,000 ) $ 0.15 Outstanding, January 31, 2021 9,095,000 $ 0.18 Granted 750,000 $ 0.32 Expired (4,776,250 ) $ 0.17 Exercised (3,968,750 ) $ 0.15 Outstanding January 31, 2022 1,100,000 $ 0.42 As at January 31, 2022, the Company had the following share purchase options outstanding and exercisable: Outstanding Exercisable Exercise Price Remaining Life Expiry Date 80,000 80,000 $1.02 3.46 July 17, 2025 70,000 - $0.54 0.11 March 10, 2022 200,000 200,000 $0.54 0.17 March 30, 2022 250,000 187,500 $0.36 0.15 March 23, 2022 250,000 125,000 $0.35 0.86 December 9, 2022 250,000 125,000 $0.25 1.50 July 30, 2023 1,100,000 780,000 $0.42 0.86

Capital Stock

Capital Stock	12 Months Ended
	Jan. 31, 2022
Disclosure of classes of share capital [abstract]
Capital Stock [Text Block]	11. Capital Stock The Company is authorized to issue the following shares: Unlimited number of common shares without par value a) Common shares The holders of common shares are entitled to receive dividends which are declared from time to time and are entitled to one vote per share at meetings of the Company. All shares are ranked equally with regards to the Company's residual assets. At January 31, 2022, the Company has 109,051,292 common shares issued and outstanding. b) Share issuances During the year ended January 31, 2022 On March 5, 2021, the Company closed a private placement of 3,114,569 units at $0.35 per unit for a consideration of $1,090,085. Each unit is comprised of one common share and one common share purchase warrant, with each warrant exercisable into a common share of the Company at an exercise price of $0.50 per share for a period of 24 months. The Black-Scholes option pricing model was used to determine the fair value of the warrants using the following weight average assumptions: Expected dividend yield of 0%; risk free interest rate of 0.29%; expected volatility of 131%; expected life of 2 years. The relative fair value of the warrants has been valued at $394,681 and common shares at $695,404. In connection with this private placement, the Company incurred $3,770 in share issuance costs. 3,968,750 shares were issued upon exercise of 3,968,750 options at a price of $0.15 per share for total gross proceeds of $595,313. An amount of $361,284 was reclassed from share-based payment reserve to share capital. 250,000 shares were fair valued at $36,250 and issued for services. During the year ended January 31, 2021 The Company cancelled 4,000,000 common shares pursuant to the sale of its interest in Cultivar JA (Note 5). 1,355,000 shares were issued upon exercise of 1,355,000 options at a price of $0.15 per share and 100,000 shares were issued upon exercise of 100,000 options at a price of $0.10 per share for total gross proceeds of $213,250. An amount of $108,435 was reclassed from share-based payment reserve to share capital. 100,000 shares were issued upon exercise of 100,000 warrants at a price of $0.50 per share for gross proceeds of $50,000. An amount of $7,481 was reclassed from warrant reserve to share capital. 50,000 shares were issued pursuant to the acquisition of MobileWellbeing ("MWB"), an innovative, feature rich, Telemedicine Remote Patient Monitoring platform (Note 8) 58,824 shares were issued at a price of $0.34 for a total consideration of $20,000. $8,333 was expensed to consulting services during the year ended January 31, 2021, while the remaining $11,667 is included in prepaid expenses as at January 31, 2021. c) Warrants Continuity of the Company's warrants is as follows: Number of Warrants Weighted Average Exercise Price Outstanding, January 31, 2020 1,648,000 $ 0.50 Exercised (100,000 ) $ 0.50 Outstanding, January 31, 2021 1,548,000 $ 0.50 Issued 3,114,569 $ 0.50 Expired (1,548,000 ) $ 0.50 Outstanding, January 31, 2022 3,114,569 $ 0.50 As at January 31, 2022, the Company had the following warrants outstanding: Outstanding Exercise Price Remaining Life (Years) Expiry Date 3,114,569 $0.50 1.09 March 5, 2023

Related Party Transactions

Related Party Transactions	12 Months Ended
	Jan. 31, 2022
Disclosure of transactions between related parties [abstract]
Related Party Transactions [Text Block]	12. Related Party Transactions Related parties include key management personnel, the Board of Directors, close family members and enterprises that are controlled by these individuals as well as certain persons performing similar functions. Key management of the Company are members of the Board of Directors, the Chief Executive Officer ("CEO"), the Chief Financial Officer ("CFO") and the Chief Operating Officer ("COO"). Transactions with key management personnel not disclosed elsewhere in the financial statements include the following: Year ended January 31, 2022 Year ended Management fees to the CEO $ 109,500 $ 99,500 Management fees to a prior director - 6,000 Management fees to the COO 92,000 68,000 Management fees to the CFO 68,345 43,550 Total Management fees $ 269,845 $ 217,050 Vehicle expense to the CEO 18,000 12,000 Vehicle expenses to the COO 18,000 10,500 Rent to the CEO included in rent expense 28,500 21,500 $ 334,345 $ 261,050 During the year ended January 31, 2022, the Company paid $127,000 (January 31, 2021: $61,329) being marketing expenses to companies controlled by the children of the CEO. As of January 31, 2022, there was $nil due to any related parties (January 31, 2021- $nil). During the year ended January 31, 2022, there was $12,995 advanced to the CEO to meet Company expenses (2021: $12,995) and included in prepaid expenses.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Jan. 31, 2022
Disclosure Of Commitments And Contingencies [Abstract]
Commitments and Contingencies [Text Block]	13. Commitments and Contingencies Effective July 1, 2020, the Company signed a two-year contract with a corporation owned and controlled by the CEO to pay monthly compensation of $8,500 for CEO services which effective September 1, 2021 was revised to $10,000 per month. In addition, the Company is obligated to pay monthly rent for $2,000 and an additional $1,500 for the use of a personal vehicle. Effective July 1, 2020, the Company signed a two-year contract with a corporation owned and controlled by the COO to pay monthly compensation of $6,000 for COO services which effective May 1, 2021, is revised to $8,500 per month. In addition, the Company is obligated to pay an additional $1,500 for the use of a personal vehicle.

Financial Instruments

Financial Instruments	12 Months Ended
	Jan. 31, 2022
Disclosure of detailed information about financial instruments [abstract]
Financial Instruments [Text Block]	14. Financial Instruments The fair value of the Company's accounts receivables and accounts payable, approximate carrying value, due to their short-term nature. The Company's cash is measured at fair value under the fair value hierarchy based on level one quoted prices in active markets for identical assets or liabilities. Financial risk management and objectives The Company's activities expose it to a variety of financial risks: credit risk, liquidity risk, and market risk (including interest rate risk, foreign currency risk, and commodity price risk). The Company thoroughly examines the various financial risks to which it is exposed and assesses the impact and likelihood of those risks. Where material, these risks are reviewed and monitored by the Board of Directors. Credit risk Credit risk is the risk of an unexpected loss if a customer or third party to a financial instrument fails to meet its contractual obligations. The Company is exposed to credit risk as During the year ended January 31, 2022, one customer represented 100% of the total revenue and represented 100% of the total accounts receivable. Liquidity risk Liquidity risk is the risk that the Company will not have sufficient cash resources to meet its financial obligations as they come due. The Company's liquidity and operating results may be adversely affected if its access to the capital market is hindered, whether as a result of a downturn in stock market conditions generally or matters specific to the Company. The Company generates cash flows primarily from its financing activities. The Company manages its liquidity needs by carefully monitoring scheduled costs. Liquidity is measured in various time bands, on day to day and week-to-week basis, as well as on long term liquidity needs over 180 day to 360 day look out periods. Funding for long term liquidity needs is based on the ability of the Company to successfully complete private placements. As at January 31, 2022, the Company had cash and cash equivalents of $211,302 to settle current liabilities of $349,672. Market Risk Market risk is the risk of loss that may arise from changes in market factors such as interest rates, commodity and equity prices, and foreign exchange rates. (a) Interest rate risk Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company is not exposed to significant interest rate risk. (b) Price risk The Company is not exposed to significant price risk as it does not possess investments in publicly traded securities. (c) Currency risk Currency risk is the risk that the fair value of future cash flows of a financial instrument denominated in a foreign currency will fluctuate because of changes in foreign exchange rates. Effective sale of the Company's interest in Cultivar JA in March 2020, the Company has no exposure to any currency except Canadian dollars.

Capital Management

Capital Management	12 Months Ended
	Jan. 31, 2022
Disclosure Of Capital Management [Abstract]
Capital Management [Text Block]	15. Capital Management The Company considers its capital to be shareholders' equity, which is comprised of share capital and deficit, which as at January 31, 2022 totaled $886,985. The Company's capital structure is adjusted based on the funds available to the Company such that it may continue to seek new opportunities. The Board of Directors does not establish quantitative return on capital criteria, but rather relies on the expertise of management and other professionals to sustain future development of the business. The sources of future funds presently available to the Company are through the sale of equity capital or debt of the Company. The ability of the Company to arrange such financing in the future will depend in part upon the prevailing capital market conditions as well as the business performance of the Company. There can be no assurance that the Company will be successful in its efforts to arrange additional financing, if needed, on terms satisfactory to the Company. Management reviews its capital management approach on an ongoing basis and believes that this approach, given the relative size of the Company, is reasonable. The Company is not subject to externally imposed capital restrictions.

Business Segment and Concentrat

Business Segment and Concentration	12 Months Ended
	Jan. 31, 2022
Disclosure of operating segments [abstract]
Business Segment and Concentration [Text Block]	16. Business Segment and Concentration The Company, through its subsidiaries, is currently focused on artificial intelligence ("AI") technologies which are targeting two specific areas: 1) workplace health and safety and 2) healthcare. All assets are located in Canada except property and equipment for $76,255 which is located in India. During the year ended January 31, 2022, one customer represented 100% of the total revenue and represented 100% of the total accounts receivable.

Income Taxes

Income Taxes	12 Months Ended
	Jan. 31, 2022
Major components of tax expense (income) [abstract]
Income Taxes [Text Block]	17. Income Taxes The following is a reconciliation of income taxes attributable to operations computed at the statutory tax rates to income tax recovery. January 31, 2022 January 31, 2021 Loss for the period $ (1,882,178 ) $ (1,584,533 ) Tax rate 27% 27% Expected income tax recoverable at statutory rate (508,000 ) (428,000 ) Change due to acquisition, tax rates, and other - (32,131 ) Non-deductible items 54,000 166,000 Share issuance costs (1,000 ) (26,000 ) Expired non-capital losses - 350,282 Change in unrecognized deductible temporary differences 455,000 (30,151 ) Total income tax recovery $ - $ - Deferred tax assets The significant components of the Company's deferred tax assets that have not been included on the consolidated statement of financial position are as follows: January 31, 2022 January 31, 2021 Non-capital losses available for future period $ 1,821,000 $ 1,381,000 Share issuance costs 13,000 19,000 Property equipment and intangible assets 22,000 1,000 Total deferred tax assets 1,856,000 1,401,000 Less: Unrecognized deferred tax assets (1,856,000 ) (1,401,000 ) Net deferred tax assets $ - $ - The significant components of the Company's unrecognized temporary differences and tax losses are as follows: January 31, 2022 Expiry Date January 31, 2021 Non-capital losses $ 6,745,000 2027 - 2042 5,116,666 Share issuance costs $ 47,000 2042 - 2046 69,003 Property equipment and intangible assets $ 84,000 No expiry 5,180 Tax attributes are subject to review and potential adjustment by tax authorities.

Significant Accounting Polici_2

Significant Accounting Policies (Policies)	12 Months Ended
	Jan. 31, 2022
Disclosure Of Significant Accounting Policies [Abstract]
Cash [Policy Text Block]	Cash Cash comprises of cash held at banks and amounts held in trust. The majority of the Company's cash is held in a major financial institution. The Company does not invest in any asset-backed deposits or investments.
Income taxes [Policy Text Block]	Income taxes Income tax on profit or loss for the period comprises of current and deferred tax. Current tax is the expected tax paid or payable on the taxable income for the period, using tax rates enacted or substantively enacted at the statement of financial position date, and any adjustment to tax paid or payable in respect of previous periods. Deferred tax is recorded by providing for temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. A deferred tax asset is recognized only to the extent that it is probable that future taxable profits will be available against which the asset can be utilized. Deferred tax assets are reduced to the extent that it is no longer probable that the related tax benefit will be realized. The effect on deferred tax assets and liabilities of a change in income tax rates is recognized in the period that includes the date of the enactment or substantive enactment of the change. Deferred tax assets and liabilities are presented separately except where there is a right of set-off within fiscal jurisdictions
Foreign currency translation [Policy Text Block]	Foreign currency translation Foreign currency transactions are translated into Canadian dollars as follows: At the transaction date, each asset, liability, revenue and expense denominated in a foreign currency is translated into Canadian dollars by the use of the exchange rate in effect at that date. At the period-end date, unsettled monetary assets and liabilities are translated into Canadian dollars by using the exchange rate in effect at the year-end date and the related translation differences are recognized in net loss. Non-monetary assets and liabilities that are measured at historical cost are translated into Canadian dollars by using the exchange rate in effect at the date of the initial transaction and are not subsequently restated. Non-monetary assets and liabilities that are measured at fair value or a revalued amount are translated into Canadian dollars by using the exchange rate in effect at the date the value is determined, and the related translation differences are recognized in net loss or other comprehensive loss consistent with where the gain or loss on the underlying non-monetary asset or liability has been recognized.
Share Capital [Policy Text Block]	Share Capital Common shares and warrants are classified as shareholders' equity. Incremental costs directly attributable to the issue of common shares are recognized as a reduction of shareholders' equity, net of tax. The Company has adopted a relative fair value method with respect to the measurement of common shares and warrants issued as private placement units. The relative fair value method allocates value to each component on a pro-rata basis, based on the fair value of the components calculated independently of one another. The Company considers the market value of the common shares issued as fair value and measures the fair value of the warrant component of the unit using the Black-Scholes option pricing model. The unit value is then allocated, pro-rata, between the two components, with fair value attributed to the warrants being recorded to the Company's warrant reserve.
Loss per share [Policy Text Block]	Loss per share Loss per share is computed by dividing the net loss applicable to common shares of the Company by the weighted average number of common shares outstanding for the relevant period. Diluted loss per common share is computed by dividing the net loss applicable to common shares by the sum of the weighted average number of common shares issued and outstanding and all additional common shares that would have been outstanding, if potentially dilutive instruments were converted.
Share-based payments [Policy Text Block]	Share-based payments The Company grants stock options to buy common shares of the Company to consultants and service providers. The Company recognizes share-based compensation expense based on the estimated fair value of the options. A fair value measurement is made for each vesting instalment within each option grant and is determined using the Black-Scholes option-pricing model. The fair value of the options is recognized over the vesting period of the options granted as both share-based compensation expense and reserves. This includes a forfeiture estimate, which is revised for actual forfeitures in subsequent periods. The reserves account is subsequently reduced if the options are exercised, and the amount initially recorded is then credited to capital stock. In situations where equity instruments are issued to non-employees and some or all of the goods or services received by the entity as consideration cannot be specifically identified, they are measured at the fair value of the share-based payment. Otherwise, share-based payments are measured at the fair value of the goods or services received.
Property and equipment: [Policy Text Block]	Property and equipment Property and equipment is carried at cost, less accumulated amortization and accumulated impairment losses. The cost of the item of property and equipment consists of the purchase price, and any costs directly attributable to bringing the asset to the location and condition necessary for its intended use. An item of property and equipment is derecognized upon disposal or when no future economic benefits are expected to arise from the continued use of the asset. Any gain or loss arising on disposal of the asset, determined as the difference between the net disposal proceeds and the carrying amount of the asset, is recognized in the consolidated statement of loss and comprehensive loss. The cost of repairs and maintenance is expensed as incurred. The Company amortizes its property and equipment using the following rates: Equipment 30% per annum, declining balance
Intangible assets [Policy Text Block]	Intangible assets Intangible assets are measured at cost less accumulated amortization and accumulated impairment losses. Amortization is recorded on a straight-line basis over the estimated useful life of the asset acquired, which varies depending on the nature of the intangible asset. Intangible assets are amortized from the date when they are available for use. The estimated useful life is reviewed at the end of each reporting period with the effect of any changes in estimate being accounted for on a prospective basis. Internally incurred development costs are recognized as intangible assets when the following criteria are met: a) b) c) d) e) f) Intangible assets may relate to the Company's external development expenditures in relation to intellectual property development. Development expenditures that do not meet these criteria are recognized as an expense as incurred. Intangible assets with definite lives are assessed for impairment whenever there is an indication that the intangible asset may be impaired. These intangible assets will be amortized when they are ready for use. The amortization period and the amortization method are reviewed at the end of each reporting period. Changes in the expected useful life or the expected pattern of consumption of future economic benefits embodied in the asset are accounted for by changing the amortization period or method, as appropriate, and are treated as changes in accounting estimates on a prospective basis.
Impairment [Policy Text Block]	Impairment The carrying amount of the Company's assets is reviewed for an indication of impairment at the end of each reporting period. If an indication of impairment exists, the Company makes an estimate of the asset's recoverable amount. Individual assets are grouped for impairment assessment purposes at the lowest level at which there are identifiable cash flows that are largely independent of the cash flows of other groups of assets. Recoverable amount of an asset group is the higher of its fair value less costs to sell and its value in use. In assessing value in use, the estimated future cash flows are adjusted for the risks specific to the asset group and are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money. Where the carrying amount of an asset group exceeds its recoverable amount, the asset group is considered impaired and is written down to its recoverable amount. Impairment losses are recognized in profit or loss. An assessment is made at each reporting date as to whether there is any indication that previously recognized impairment losses may no longer exist or may have decreased. If such indication exists, the recoverable amount is estimated. A previously recognized impairment loss is reversed only if there has been a change in the estimates used to determine the asset's recoverable amount. An impairment loss is reversed only to the extent that the asset's carrying amount does not exceed the carrying amount that would have been determined, net of depreciation, if no impairment loss had been recognized.
Financial Instruments [Policy Text Block]	Financial Instruments Financial assets and financial liabilities are recognized on the consolidated statements of financial position when the Company becomes a party to the contractual provisions of the financial instrument. The following is the Company's accounting policy for financial instruments under IFRS 9: Classification The Company classifies its financial instruments in the following categories: at fair value through profit and loss ("FVTPL"), at fair value through other comprehensive income (loss) ("FVTOCI") or at amortized cost. The Company determines the classification of financial assets at initial recognition. The classification of debt instruments is driven by the Company's business model for managing the financial assets and their contractual cash flow characteristics. Equity instruments that are held for trading are classified as FVTPL. For other equity instruments, on the day of acquisition the Company can make an irrevocable election (on an instrument-by-instrument basis) to designate them as at FVTOCI. Financial liabilities are measured at amortized cost, unless they are required to be measured at FVTPL (such as instruments held for trading or derivatives) or if the Company has opted to measure them at FVTPL. Measurement Financial assets and liabilities at amortized cost Financial assets and liabilities at amortized cost are initially recognized at fair value plus or minus transaction costs, respectively, and subsequently carried at amortized cost less any impairment. Financial assets and liabilities at FVTPL Financial assets and liabilities carried at FVTPL are initially recorded at fair value and transaction costs are expensed in the consolidated statements of loss and comprehensive loss. Realized and unrealized gains and losses arising from changes in the fair value of the financial assets and liabilities held at FVTPL are included in the consolidated statements of loss and comprehensive loss in the period in which they arise. Debt investments at FVOCI These assets are subsequently measured at fair value. Interest income calculated using the effective interest method, foreign exchange gains and losses and impairment are recognized in profit or loss. Other net gains and losses are recognized in OCI. On derecognition, gains and losses accumulated in OCI are reclassified to profit or loss. Equity investments at FVOCI These assets are subsequently measured at fair value. Dividends are recognized as income in profit or loss unless the dividend clearly represents a recovery of part of the cost of the investment. Other net gains and losses are recognized in OCI and are never reclassified to profit or loss. Impairment of financial assets at amortized cost The Company recognizes a loss allowance for expected credit losses on financial assets that are measured at amortized cost. At each reporting date, the Company measures the loss allowance for the financial asset at an amount equal to the lifetime expected credit losses if the credit risk on the financial asset has increased significantly since initial recognition. If at the reporting date, the financial asset has not increased significantly since initial recognition, the Company measures the loss allowance for the financial asset at an amount equal to the twelve month expected credit losses. The Company shall recognize in the consolidated statements of loss and comprehensive loss, as an impairment gain or loss, the amount of expected credit losses (or reversal) that is required to adjust the loss allowance at the reporting date to the amount that is required to be recognized. Derecognition Financial assets The Company derecognizes financial assets only when the contractual rights to cash flows from the financial assets expire, or when it transfers the financial assets and substantially all of the associated risks and rewards of ownership to another entity. Financial liabilities The Company derecognizes a financial liability when its contractual obligations are discharged or cancelled or expired. The Company also derecognizes a financial liability when the terms of the liability are modified such that the terms and / or cash flows of the modified instrument are substantially different, in which case a new financial liability based on the modified terms is recognized at fair value. Gains and losses on derecognition are generally recognized in profit or loss. The Company's financial assets and liabilities are classified as follows: Asset or Liability Classification Cash FVTPL Accounts receivable Amortized cost Accounts payable Amortized cost The Company determines the fair value of financial instruments according to the following hierarchy based on the amount of observable inputs used to value the instrument. Level 1 – Quoted prices are available in active markets for identical assets or liabilities as of the reporting date. Active markets are those in which transactions occur in sufficient frequency and volume to provide pricing information on an ongoing basis. Level 2 – Pricing inputs are other than quoted prices in active markets included in Level 1. Prices in Level 2 are either directly or indirectly observable as of the reporting date. Level 2 valuations are based on inputs, including quoted forward prices for commodities, time value and volatility factors, which can be substantially observed or corroborated in the marketplace. Level 3 – Valuations in this level are those with inputs for the asset or liability that are not based on observable market data. Cash has been measured at fair value using Level 1 inputs. Impairment of financial assets Financial assets are assessed at each reporting date to determine whether there is objective evidence that they are impaired. A financial asset is impaired if objective evidence indicates that a loss event has occurred after the initial recognition of the asset and that the loss event had a negative effect on the estimated future cash flows of that asset that can be estimated reliably. An impairment loss in respect of a financial asset measured at amortized cost is calculated as the difference between its carrying amount and the present value of the estimated future cash flows discounted at the asset's original effective interest rate. Losses are recognized in profit or loss and reflected in a separate line item. When a subsequent event causes the amount of impairment loss to decrease, the decrease in impairment loss is reversed through profit or loss. Revenue recognition Revenue is recognized at an amount that reflects the expected consideration receivable in exchange for transferring goods or services to a customer, applying the following five steps: 1. 2. 3. 4. 5. Under IFRS 15, the Company classified its revenue as being principally derived from the following source: Screening services revenue on deployment of safe entry stations for use of the Company's technology. Revenue from the sale of screening services is recognized based on the transaction price. Upfront fees as set-up fees are included in the transaction price and allocated to the performance obligation in the contract. Revenue is recognized as the performance obligations are satisfied.
New standards not yet adopted [Policy Text Block]	New standards not yet adopted Classification of Liabilities as Current or Non-Current (Amendments to IAS 1) The IASB has published Classification of Liabilities as Current or Non-Current (Amendments to IAS 1) which clarifies the guidance on whether a liability should be classified as either current or non-current. The amendment a) clarify that the classification of liabilities as current or non-current should only be based on rights that are in place "at the end of the reporting period" b) clarify that classification is unaffected by expectations about whether an entity will exercise its right to defer settlement of a liability, and c) make clear that settlement includes transfers to the counterparty of cash, equity instruments, other assets or services that result in extinguishment of the liability. This amendment is effective for annual periods beginning on or after January 1, 2022. Earlier application is permitted. The extent of the impact of adoption of this amendment has not yet been determined.

Acquisitions (Tables)

Acquisitions (Tables)	12 Months Ended
	Jan. 31, 2022
Disclosure of detailed information about business combination [abstract]
Disclosure of fair value of the acquired assets and liabilities assumed [Table Text Block]	Assets acquired by the Company: Cash $ 3,448 Prepaid expenses 1,125 Liabilities assumed by the Company: Accounts payable and accrued liabilities (19,127 ) Loans payable (107,525 ) Net liabilities assumed (122,079 ) Fair value of shares issued (1,367,992 ) Loss on acquisition $ (1,490,071 )

Sale of interest in Cultivar _2

Sale of interest in Cultivar JA Limited (Tables)	12 Months Ended
	Jan. 31, 2022
Disclosure Of Sale Of Interest In Cultivar Ja Limited [Abstract]
Disclosure of Income (loss) from discontinued operations [Table Text Block]	For the For the Expenses: Amortization $ - $ 2,871 Interest expense - 687 Travel, entertainment and related - 2,014 Net loss for the period prior to the sale transaction - (5,572 ) Gain on divestiture - 351,868 Income (loss) from discontinued operations, net of tax $ - $ 346,296

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Jan. 31, 2022
Property, plant and equipment [abstract]
Disclosure of property and equipment [Table Text Block]	Equipment Leasehold Improvement Total Cost Balance as at January 31, 2020 $ 21,953 $ 9,916 $ 31,869 Discontinuance of business (Note 5) (8,585 ) (9,916 ) (18,501 ) Balance as at January 31, 2021 $ 13,368 $ - $ 13,368 Additions 84,755 - 84,755 Balance as at January 31, 2022 $ 98,123 $ - $ 98,123 Accumulated Amortization Balance as at January 31, 2020 $ 5,749 $ 5,929 $ 11,678 Amortization 3,509 - 3,509 Discontinuance of business (Note 5) (4,078 ) (5,929 ) (10,007 ) Balance as at January 31, 2021 $ 5,180 $ - $ 5,180 Amortization 16,688 - 16,688 Balance as at January 31, 2022 $ 21,868 $ - $ 21,868 Net Carrying Amounts As at January 31, 2022 $ 76,255 $ - $ 76,255 As at January 31, 2021 $ 8,188 $ - $ 8,188

Intangible Assets (Tables)

Intangible Assets (Tables)	12 Months Ended
	Jan. 31, 2022
Disclosure of detailed information about intangible assets [abstract]
Disclosure of detailed information about purchase price allocation of intangible assets [Table Text Block]	Consideration Cash consideration on closing $ 25,000 Issued shares (50,000 shares issued at $1.06/share) 53,000 $ 78,000 Purchase Price allocation Intangible asset- MWB remote patient monitoring platform $ 78,000 $ 78,000
Disclosure of detailed information about intangible assets [Table Text Block]	MWB IDSS Total Cost Balance at January 31, 2020 $ - $ - $ - Acquisition 78,000 - 78,000 Additions 13,970 156,040 170,010 Balance at January 31, 2021 $ 91,970 $ 156,040 $ 248,010 Additions 46,591 286,778 333,369 Balance at January 31, 2022 $ 138,561 $ 442,818 $ 581,379 Accumulated amortization: Balance as at January 1, 2020 $ - $ - $ - Amortization - - - Balance as at January 31, 2021 $ - $ - $ - Amortization 18,990 43,611 62,601 Balance as at January 31, 2022 $ 18,990 $ 43,611 $ 62,601 Net Book Value Balance, January 31, 2021 $ 91,970 $ 156,040 $ 248,010 Balance, January 31, 2022 $ 119,571 $ 399,207 $ 518,778

Leases (Tables)

Leases (Tables)	12 Months Ended
	Jan. 31, 2022
Lease liabilities [abstract]
Disclosure of right of use assets [Table Text Block]	Balance as at January 31, 2020 $ 12,192 Amortization (2,871 ) Discontinuance of business (Note 5) (9,321 ) As at January 31, 2022 and 2021 $ -
Disclosure of lease liability interest expense recognized [Table Text Block]	Balance as at January 31, 2020 $ 15,189 Interest expense 687 Lease payments made during the year (2,129 ) Discontinuance of business (Note 5) (13,747 ) As at January 31, 2022 and 2021 $ -
Disclosure of lease liability [Table Text Block]	January 31, 2022 January 31, 2021 Lease liability - current $ - $ - Lease liability - non- current - Total lease liability $ - $ -

Stock-based Compensation (Table

Stock-based Compensation (Tables)	12 Months Ended
	Jan. 31, 2022
Disclosure of terms and conditions of share-based payment arrangement [line items]
Disclosure of number and weighted average exercise prices of share options [Table Text Block]	Number of Weighted Average Outstanding, January 31, 2020 350,000 $ 0.10 Granted 10,450,000 $ 0.18 Expired (250,000 ) $ 0.10 Exercised (1,455,000 ) $ 0.15 Outstanding, January 31, 2021 9,095,000 $ 0.18 Granted 750,000 $ 0.32 Expired (4,776,250 ) $ 0.17 Exercised (3,968,750 ) $ 0.15 Outstanding January 31, 2022 1,100,000 $ 0.42
Disclosure of number and weighted average remaining contractual life of outstanding share options [Table Text Block]	Outstanding Exercisable Exercise Price Remaining Life Expiry Date 80,000 80,000 $1.02 3.46 July 17, 2025 70,000 - $0.54 0.11 March 10, 2022 200,000 200,000 $0.54 0.17 March 30, 2022 250,000 187,500 $0.36 0.15 March 23, 2022 250,000 125,000 $0.35 0.86 December 9, 2022 250,000 125,000 $0.25 1.50 July 30, 2023 1,100,000 780,000 $0.42 0.86
Stock Options Granted in October 2018 [Member] | Consultant [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Disclosure of detailed information about options, valuation assumptions [Table Text Block]	Risk free rate 2.26% Expected dividends 0% Expected forfeiture rate 0% Expected volatility 100% Expected life 2 years Unvested stock-based compensation expense as of January 31, 2021 $ -
Stock Options Granted in November 2018 [Member] | Consultant [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Disclosure of detailed information about options, valuation assumptions [Table Text Block]	Risk free rate 2.30% Expected dividends 0% Expected forfeiture rate 0% Expected volatility 100% Expected life 3 years Unvested stock-based compensation expense as of January 31, 2021 $ -
Stock Options Granted on April 6, 2020 [Member] | Directors, officers and consultants [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Disclosure of detailed information about options, valuation assumptions [Table Text Block]	Risk free rate 0.47% Expected dividends 0% Expected forfeiture rate 0% Expected volatility 135% Expected life 1 year Unvested stock-based compensation expense as of January 31, 2021 $ -
Stock Options Granted on July 17, 2020 [Member] | Consultant [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Disclosure of detailed information about options, valuation assumptions [Table Text Block]	Risk free rate 0.35% Expected dividends 0% Expected forfeiture rate 0% Expected volatility 207% Expected life 5 years Unvested stock-based compensation expense as of January 31, 2021 $ 34,246
Stock Options Granted on September 17, 2020 [Member] | Consultant [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Disclosure of detailed information about options, valuation assumptions [Table Text Block]	Risk free rate 0.26% Expected dividends 0% Expected forfeiture rate 0% Expected volatility 189% Expected life 1.5 years Unvested stock-based compensation expense as of January 31, 2021 $ -
Stock Options Granted on September 21, 2020 [Member] | Consultant [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Disclosure of detailed information about options, valuation assumptions [Table Text Block]	Risk free rate 0.23% Expected dividends 0% Expected forfeiture rate 0% Expected volatility 188% Expected life 1 year Unvested stock-based compensation expense as of January 31, 2021 $ 18,958
Stock Options Granted on March 23, 2021 [Member] | Consultant [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Disclosure of detailed information about options, valuation assumptions [Table Text Block]	Risk free rate 0.26% Expected dividends 0% Expected forfeiture rate 0% Expected volatility 134.3% Expected life 1 year Unvested stock-based compensation expense as of January 31, 2022 $ 1,834
Stock Options Granted on June 9, 2021 [Member] | Consultant [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Disclosure of detailed information about options, valuation assumptions [Table Text Block]	Risk free rate 0.32% Expected dividends 0% Expected forfeiture rate 0% Expected volatility 146.38% Expected life 1.5 years Unvested stock-based compensation expense as of January 31, 2022 $ 6,778
Stock Options Granted on July 30, 2021 [Member] | Consultant [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Disclosure of detailed information about options, valuation assumptions [Table Text Block]	Risk free rate 0.38% Expected dividends 0% Expected forfeiture rate 0% Expected volatility 131.33% Expected life 1.5 years Unvested stock-based compensation expense as of January 31, 2022 $ 7,826

Capital Stock (Tables)

Capital Stock (Tables)	12 Months Ended
	Jan. 31, 2022
Disclosure of classes of share capital [abstract]
Disclosure of continuity of warrants [Table Text Block]	Number of Warrants Weighted Average Exercise Price Outstanding, January 31, 2020 1,648,000 $ 0.50 Exercised (100,000 ) $ 0.50 Outstanding, January 31, 2021 1,548,000 $ 0.50 Issued 3,114,569 $ 0.50 Expired (1,548,000 ) $ 0.50 Outstanding, January 31, 2022 3,114,569 $ 0.50
Disclosure of number, exercise price and remaining life of outstanding warrants [Table Text block]	Outstanding Exercise Price Remaining Life (Years) Expiry Date 3,114,569 $0.50 1.09 March 5, 2023

Related Party Transactions (Tab

Related Party Transactions (Tables)	12 Months Ended
	Jan. 31, 2022
Disclosure of transactions between related parties [abstract]
Disclosure of transactions with key management personnel [Table Text Block]	Year ended January 31, 2022 Year ended Management fees to the CEO $ 109,500 $ 99,500 Management fees to a prior director - 6,000 Management fees to the COO 92,000 68,000 Management fees to the CFO 68,345 43,550 Total Management fees $ 269,845 $ 217,050 Vehicle expense to the CEO 18,000 12,000 Vehicle expenses to the COO 18,000 10,500 Rent to the CEO included in rent expense 28,500 21,500 $ 334,345 $ 261,050

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Jan. 31, 2022
Major components of tax expense (income) [abstract]
Disclosure of reconciliation of provision for income taxes [Table Text Block]	January 31, 2022 January 31, 2021 Loss for the period $ (1,882,178 ) $ (1,584,533 ) Tax rate 27% 27% Expected income tax recoverable at statutory rate (508,000 ) (428,000 ) Change due to acquisition, tax rates, and other - (32,131 ) Non-deductible items 54,000 166,000 Share issuance costs (1,000 ) (26,000 ) Expired non-capital losses - 350,282 Change in unrecognized deductible temporary differences 455,000 (30,151 ) Total income tax recovery $ - $ -
Disclosure of deferred taxes [Table Text Block]	January 31, 2022 January 31, 2021 Non-capital losses available for future period $ 1,821,000 $ 1,381,000 Share issuance costs 13,000 19,000 Property equipment and intangible assets 22,000 1,000 Total deferred tax assets 1,856,000 1,401,000 Less: Unrecognized deferred tax assets (1,856,000 ) (1,401,000 ) Net deferred tax assets $ - $ -
Disclosure of unrecognized temporary differences and tax losses [Table Text Block]	January 31, 2022 Expiry Date January 31, 2021 Non-capital losses $ 6,745,000 2027 - 2042 5,116,666 Share issuance costs $ 47,000 2042 - 2046 69,003 Property equipment and intangible assets $ 84,000 No expiry 5,180

Organization and Nature of Op_2

Organization and Nature of Operations (Narrative) (Details) - shares	Mar. 27, 2020	Jul. 16, 2018	Feb. 15, 2018	Jan. 31, 2022	Sep. 23, 2019
Cultivar Holdings Ltd. [Member]
Disclosure of detailed information about business combination [line items]
Number of aggregate common shares issued					97,439,900
Ownership interest percentage acquired				100.00%
Cultivar JA Limited [Member]
Disclosure of detailed information about business combination [line items]
Ownership interest percentage acquired	49.00%		49.00%
Remaining ownership percentage			51.00%
CannIP Holdings Inc. [Member]
Disclosure of detailed information about business combination [line items]
Number of aggregate common shares issued		29,800,000
Ownership interest percentage acquired		100.00%		100.00%

Basis of Presentation and Goi_2

Basis of Presentation and Going Concern (Narrative) (Details) - CAD ($)	Mar. 27, 2020	Jul. 16, 2018	Feb. 15, 2018	Jan. 31, 2022	Jan. 31, 2021
Disclosure Of Basis Of Presentation And Going Concern [Line Items]
Cash and cash equivalents				$ 211,302	$ 480,051
Working capital				291,952
Accumulated deficit				$ 6,015,189	$ 4,133,011
Cultivar Holdings Ltd. [Member]
Disclosure Of Basis Of Presentation And Going Concern [Line Items]
Ownership interest percentage acquired				100.00%
CannIP Holdings Inc. [Member]
Disclosure Of Basis Of Presentation And Going Concern [Line Items]
Ownership interest percentage acquired		100.00%		100.00%
Cultivar JA Limited [Member]
Disclosure Of Basis Of Presentation And Going Concern [Line Items]
Ownership interest percentage acquired	49.00%		49.00%

Significant Accounting Polici_3

Significant Accounting Policies (Narrative) (Details)	12 Months Ended
	Jan. 31, 2022
Equipment [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Property and equipment amortization rate	30.00%

Acquisitions (Narrative) (Detai

Acquisitions (Narrative) (Details) - Cultivar Holdings Ltd. [Member]	12 Months Ended
	Jan. 31, 2020CAD ($)Share$ / shares
Disclosure of detailed information about business combination [line items]
Number of shares issued under consideration | Share	6,514,249
Shares issued, price per share | $ / shares	$ 0.21
Consideration value as of acquisition date | $	$ 1,367,992

Acquisitions (Disclosure of fai

Acquisitions (Disclosure of fair value of the acquired assets and liabilities assumed) (Details) - Cultivar Holdings Ltd. [Member]	Jan. 31, 2020CAD ($)
Assets acquired by the Company:
Cash	$ 3,448
Prepaid expenses	1,125
Liabilities assumed by the Company:
Accounts payable and accrued liabilities	(19,127)
Loans payable	(107,525)
Net liabilities assumed	(122,079)
Fair value of shares issued	(1,367,992)
Loss on acquisition	$ (1,490,071)

Sale of interest in Cultivar _3

Sale of interest in Cultivar JA Limited (Narrative) (Details) - CAD ($)	Mar. 27, 2020	Feb. 15, 2018	Jan. 31, 2021
Disclosure of analysis of single amount of discontinued operations [line items]
Sale of Cultivar Jamaica (Shares)			(4,000,000)
Sale of Cultivar Jamaica			$ 413,445
Cultivar JA Limited [Member]
Disclosure of analysis of single amount of discontinued operations [line items]
Ownership interest percentage	49.00%	49.00%
Sale of Cultivar Jamaica (Shares)	(4,000,000)
Additional shares terminated	500,000
Sale of Cultivar Jamaica	$ 540,000

Sale of interest in Cultivar _4

Sale of interest in Cultivar JA Limited (Disclosure of Income (loss) from discontinued operations) (Details) - CAD ($)	12 Months Ended
	Jan. 31, 2022	Jan. 31, 2021
Disclosure Of Sale Of Interest In Cultivar Ja Limited [Line Items]
Amortization	$ 79,288	$ 3,509
Travel, entertainment and related	33,642	31,308
Income (loss) from discontinued operations, net of tax	0	346,296
Cultivar JA Limited [Member]
Disclosure Of Sale Of Interest In Cultivar Ja Limited [Line Items]
Amortization	0	2,871
Interest expense	0	687
Travel, entertainment and related	0	2,014
Net loss for the period prior to the sale transaction	0	(5,572)
Gain on divestiture	0	351,868
Income (loss) from discontinued operations, net of tax	$ 0	$ 346,296

Prepaid Expenses (Narrative) (D

Prepaid Expenses (Narrative) (Details) - CAD ($)	Jan. 31, 2022	Jan. 31, 2021
Disclosure of detailed information about intangible assets [line items]
Prepaid expenses	$ 49,295	$ 155,442
Study on detection technology [Member]
Disclosure of detailed information about intangible assets [line items]
Prepaid expenses	$ 0	$ 70,060

Property and Equipment (Disclos

Property and Equipment (Disclosure of property and equipment) (Details) - CAD ($)	12 Months Ended
	Jan. 31, 2022	Jan. 31, 2021
Disclosure of detailed information about property, plant and equipment [line items]
Beginning Balance	$ 8,188
Ending Balance	76,255	$ 8,188
Cost [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Beginning Balance	13,368	31,869
Additions	84,755
Discontinuance of business		18,501
Ending Balance	98,123	13,368
Accumulated Amortization [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Beginning Balance	(5,180)	(11,678)
Amortization	(16,688)	(3,509)
Discontinuance of business		(10,007)
Ending Balance	(21,868)	(5,180)
Equipment [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Beginning Balance	8,188
Ending Balance	76,255	8,188
Equipment [Member] | Cost [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Beginning Balance	13,368	21,953
Additions	84,755
Discontinuance of business		8,585
Ending Balance	98,123	13,368
Equipment [Member] | Accumulated Amortization [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Beginning Balance	(5,180)	(5,749)
Amortization	(16,688)	(3,509)
Discontinuance of business		(4,078)
Ending Balance	(21,868)	(5,180)
Leasehold Improvement [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Beginning Balance	0
Ending Balance	0	0
Leasehold Improvement [Member] | Cost [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Beginning Balance	0	9,916
Additions	0
Discontinuance of business		9,916
Ending Balance	0	0
Leasehold Improvement [Member] | Accumulated Amortization [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Beginning Balance	0	(5,929)
Amortization	0	0
Discontinuance of business		(5,929)
Ending Balance	$ 0	$ 0

Intangible Assets (Narrative) (

Intangible Assets (Narrative) (Details) - CAD ($)	1 Months Ended	12 Months Ended
	Jul. 21, 2020	Jan. 31, 2022	Jan. 31, 2021
Disclosure of detailed information about intangible assets [line items]
Purchase price in cash		$ 333,369	$ 195,010
MobileWellbeing ("MWB") [Member]
Disclosure of detailed information about intangible assets [line items]
Purchase price in cash	$ 25,000
Shares issued to acquire intangible assets	20,000
Additional shares issued to acquire intangible assets on ninetieth day of close	30,000
Consideration transferred for acquisition of intangible assets	$ 78,000
Percentage of royalty of gross sales	20.00%
Sales applicable to royalty	$ 2,500,000
Additional shares issued to acquire intangible assets on release of initial platforms	200,000
Amortization method		straight line
Estimated useful life intangible assets		5 years

Intangible Assets (Disclosure o

Intangible Assets (Disclosure of detailed information about purchase price allocation of intangible assets) (Details) - CAD ($)	1 Months Ended	12 Months Ended
	Jul. 21, 2020	Jan. 31, 2022	Jan. 31, 2021
Consideration
Cash consideration on closing		$ 333,369	$ 195,010
Purchase Price allocation
Intangible assets		518,778	$ 248,010
MobileWellbeing ("MWB") [Member]
Consideration
Cash consideration on closing	$ 25,000
Issued shares (50,000 shares issued at $1.06/share)	$ 53,000
Shares issued to acquire intangible assets, including closing	50,000		50,000
Shares issued to acquire intangible assets, value per share	$ 1.06
Total Consideration	$ 78,000
Purchase Price allocation
Intangible assets	78,000	$ 119,571	$ 91,970
Total Purchase Price allocation	$ 78,000

Intangible Assets (Disclosure_2

Intangible Assets (Disclosure of detailed information about intangible assets) (Details) - CAD ($)	12 Months Ended
	Jan. 31, 2022	Jan. 31, 2021
Disclosure of detailed information about intangible assets [line items]
Intangible assets other than goodwill at beginning of period	$ 248,010
Intangible assets other than goodwill at end of period	518,778	$ 248,010
Cost [Member]
Disclosure of detailed information about intangible assets [line items]
Intangible assets other than goodwill at beginning of period	248,010	0
Acquisition		78,000
Additions	333,369	170,010
Intangible assets other than goodwill at end of period	581,379	248,010
Accumulated amortization [Member]
Disclosure of detailed information about intangible assets [line items]
Intangible assets other than goodwill at beginning of period	0	0
Amortization	(62,601)	0
Intangible assets other than goodwill at end of period	(62,601)	0
MWB [Member]
Disclosure of detailed information about intangible assets [line items]
Intangible assets other than goodwill at beginning of period	91,970
Intangible assets other than goodwill at end of period	119,571	91,970
MWB [Member] | Cost [Member]
Disclosure of detailed information about intangible assets [line items]
Intangible assets other than goodwill at beginning of period	91,970	0
Acquisition		78,000
Additions	46,591	13,970
Intangible assets other than goodwill at end of period	138,561	91,970
MWB [Member] | Accumulated amortization [Member]
Disclosure of detailed information about intangible assets [line items]
Intangible assets other than goodwill at beginning of period	0	0
Amortization	(18,990)	0
Intangible assets other than goodwill at end of period	(18,990)	0
IDSS [Member]
Disclosure of detailed information about intangible assets [line items]
Intangible assets other than goodwill at beginning of period	156,040
Intangible assets other than goodwill at end of period	399,207	156,040
IDSS [Member] | Cost [Member]
Disclosure of detailed information about intangible assets [line items]
Intangible assets other than goodwill at beginning of period	156,040	0
Acquisition		0
Additions	286,778	156,040
Intangible assets other than goodwill at end of period	442,818	156,040
IDSS [Member] | Accumulated amortization [Member]
Disclosure of detailed information about intangible assets [line items]
Intangible assets other than goodwill at beginning of period	0	0
Amortization	(43,611)	0
Intangible assets other than goodwill at end of period	$ (43,611)	$ 0

Leases (Narrative) (Details)

Leases (Narrative) (Details) - CAD ($)	Jan. 31, 2022	Jan. 31, 2021	Jan. 31, 2020
Lease liabilities [abstract]
Right-of-use assets	$ 0	$ 0	$ 12,192
Total lease liability	$ 0	$ 0	$ 15,189

Leases (Disclosure of right of

Leases (Disclosure of right of use assets) (Details)	12 Months Ended
	Jan. 31, 2021CAD ($)
Lease liabilities [abstract]
Balance	$ 12,192
Amortization	(2,871)
Discontinuance of business	(9,321)
Balance	$ 0

Leases (Disclosure of lease lia

Leases (Disclosure of lease liability interest expense recognized) (Details) - CAD ($)	12 Months Ended
	Jan. 31, 2022	Jan. 31, 2021
Lease liabilities [abstract]
Balance	$ 0	$ 15,189
Interest expense		687
Lease payments made for discontinued operations	0	(2,129)
Discontinuance of business		(13,747)
Balance	$ 0	$ 0

Leases (Disclosure of lease l_2

Leases (Disclosure of lease liability) (Details) - CAD ($)	Jan. 31, 2022	Jan. 31, 2021	Jan. 31, 2020
Lease liabilities [abstract]
Lease liability - current	$ 0	$ 0
Lease liability - non- current		0
Total lease liability	$ 0	$ 0	$ 15,189

Stock-based Compensation (Narra

Stock-based Compensation (Narrative) (Details)	12 Months Ended
	Jan. 31, 2022CAD ($)Share$ / shares	Jan. 31, 2021CAD ($)Share$ / shares
Disclosure of terms and conditions of share-based payment arrangement [line items]
Options authorized under stock option plan as a percentage of issued and outstanding common shares	10.00%
Number of share options granted in share-based payment arrangement	750,000	10,450,000
Number of share options vested in share-based payment arrangement		100,000
Vested stock-based compensation expense | $	$ 182,996	$ 946,361
Unvested stock-based compensation expense | $	16,438	$ 53,204
Stock Options Granted in October 2018 [Member] | Consultant [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of share options granted in share-based payment arrangement		250,000
Exercise price, share options granted | $ / shares		$ 0.1
Maximum term of options granted for share-based payment arrangement		two years
Vested stock-based compensation expense | $		$ 3,311
Unvested stock-based compensation expense | $		$ 0
Stock Options Granted in October 2018 [Member] | Consultant [Member] | Vesting Tranche One [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of share options vested in share-based payment arrangement		75,000
Stock Options Granted in October 2018 [Member] | Consultant [Member] | Vesting Tranche Two [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of share options vested in share-based payment arrangement		37,500
Stock Options Granted in October 2018 [Member] | Consultant [Member] | Vesting Tranche Three [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of share options vested in share-based payment arrangement		137,500
Stock Options Granted in October 2018 [Member] | Consultant [Member] | Vesting Tranche Three, on model development [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of share options vested in share-based payment arrangement		75,000
Stock Options Granted in October 2018 [Member] | Consultant [Member] | Vesting Tranche Three, on project handover [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of share options vested in share-based payment arrangement		62,500
Stock Options Granted in November 2018 [Member] | Consultant [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of share options granted in share-based payment arrangement		100,000
Exercise price, share options granted | $ / shares		$ 0.1
Maximum term of options granted for share-based payment arrangement		three years
Vested stock-based compensation expense | $		$ 260
Unvested stock-based compensation expense | $		$ 0
Stock Options Granted in November 2018 [Member] | Consultant [Member] | Vesting Tranche One [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of share options vested in share-based payment arrangement		25,000
Stock Options Granted in November 2018 [Member] | Consultant [Member] | Vesting Tranche Two [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of share options vested in share-based payment arrangement		25,000
Stock Options Granted in November 2018 [Member] | Consultant [Member] | Vesting Tranche Three [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of share options vested in share-based payment arrangement		25,000
Stock Options Granted in November 2018 [Member] | Consultant [Member] | Vesting Tranche Four [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of share options vested in share-based payment arrangement		25,000
Stock Options Granted on April 6, 2020 [Member] | Directors, officers and consultants [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of share options granted in share-based payment arrangement		9,850,000
Exercise price, share options granted | $ / shares		$ 0.15
Maximum term of options granted for share-based payment arrangement		one (1) year
Vested stock-based compensation expense | $		$ 742,833
Unvested stock-based compensation expense | $		$ 0
Stock Options Granted on July 17, 2020 [Member] | Consultant [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of share options granted in share-based payment arrangement		80,000
Exercise price, share options granted | $ / shares		$ 1.02
Maximum term of options granted for share-based payment arrangement		five (5) years
Vested stock-based compensation expense | $	34,246	$ 40,603
Unvested stock-based compensation expense | $	0	$ 34,246
Stock Options Granted on September 10, 2020 [Member] | Consultant [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of share options granted in share-based payment arrangement		70,000
Exercise price, share options granted | $ / shares		$ 0.54
Stock Options Granted on September 10, 2020 [Member] | Consultant [Member] | Vesting Tranche One [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of share options vested in share-based payment arrangement		40,000
Stock Options Granted on September 10, 2020 [Member] | Consultant [Member] | Vesting Tranche Two [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of share options vested in share-based payment arrangement		30,000
Stock Options Granted on September 17, 2020 [Member] | Consultant [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of share options granted in share-based payment arrangement		200,000
Exercise price, share options granted | $ / shares		$ 0.54
Vested stock-based compensation expense | $		$ 81,979
Unvested stock-based compensation expense | $		$ 0
Stock Options Granted on September 21, 2020 [Member] | Consultant [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of share options granted in share-based payment arrangement		250,000
Exercise price, share options granted | $ / shares		$ 0.59
Maximum term of options granted for share-based payment arrangement		one (1) year
Vested stock-based compensation expense | $	18,958	$ 77,375
Unvested stock-based compensation expense | $	$ 0	$ 18,958
Stock Options Granted on March 23, 2021 [Member] | Consultant [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of share options granted in share-based payment arrangement	250,000
Exercise price, share options granted | $ / shares	$ 0.36
Maximum term of options granted for share-based payment arrangement	one (1) year
Vested stock-based compensation expense | $	$ 50,675
Unvested stock-based compensation expense | $	$ 1,834
Stock Options Granted on June 9, 2021 [Member] | Consultant [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of share options granted in share-based payment arrangement	250,000
Exercise price, share options granted | $ / shares	$ 0.345
Maximum term of options granted for share-based payment arrangement	18 months
Vested stock-based compensation expense | $	$ 48,672
Unvested stock-based compensation expense | $	$ 6,778
Stock Options Granted on July 30, 2021 [Member] | Consultant [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of share options granted in share-based payment arrangement	250,000
Exercise price, share options granted | $ / shares	$ 0.25
Maximum term of options granted for share-based payment arrangement	18 months
Vested stock-based compensation expense | $	$ 30,445
Unvested stock-based compensation expense | $	$ 7,826

Stock-based Compensation (Discl

Stock-based Compensation (Disclosure of detailed information about options, valuation assumptions) (Details)	12 Months Ended
	Jan. 31, 2022CAD ($)Year	Jan. 31, 2021CAD ($)Year
Disclosure of terms and conditions of share-based payment arrangement [line items]
Unvested stock-based compensation expense	$ 16,438	$ 53,204
Stock Options Granted in October 2018 [Member] | Consultant [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Risk free rate		2.26%
Expected dividends		0.00%
Expected forfeiture rate		0.00%
Expected volatility		100.00%
Option life, share options granted | Year		2
Unvested stock-based compensation expense		$ 0
Stock Options Granted in November 2018 [Member] | Consultant [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Risk free rate		2.30%
Expected dividends		0.00%
Expected forfeiture rate		0.00%
Expected volatility		100.00%
Option life, share options granted | Year		3
Unvested stock-based compensation expense		$ 0
Stock Options Granted on April 6, 2020 [Member] | Directors, officers and consultants [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Risk free rate		0.47%
Expected dividends		0.00%
Expected forfeiture rate		0.00%
Expected volatility		135.00%
Option life, share options granted | Year		1
Unvested stock-based compensation expense		$ 0
Stock Options Granted on July 17, 2020 [Member] | Consultant [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Risk free rate		0.35%
Expected dividends		0.00%
Expected forfeiture rate		0.00%
Expected volatility		207.00%
Option life, share options granted | Year		5
Unvested stock-based compensation expense	0	$ 34,246
Stock Options Granted on September 17, 2020 [Member] | Consultant [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Risk free rate		0.26%
Expected dividends		0.00%
Expected forfeiture rate		0.00%
Expected volatility		189.00%
Option life, share options granted | Year		1.5
Unvested stock-based compensation expense		$ 0
Stock Options Granted on September 21, 2020 [Member] | Consultant [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Risk free rate		0.23%
Expected dividends		0.00%
Expected forfeiture rate		0.00%
Expected volatility		188.00%
Option life, share options granted | Year		1
Unvested stock-based compensation expense	$ 0	$ 18,958
Stock Options Granted on March 23, 2021 [Member] | Consultant [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Risk free rate	0.26%
Expected dividends	0.00%
Expected forfeiture rate	0.00%
Expected volatility	134.30%
Option life, share options granted | Year	1
Unvested stock-based compensation expense	$ 1,834
Stock Options Granted on June 9, 2021 [Member] | Consultant [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Risk free rate	0.32%
Expected dividends	0.00%
Expected forfeiture rate	0.00%
Expected volatility	146.38%
Option life, share options granted | Year	1.5
Unvested stock-based compensation expense	$ 6,778
Stock Options Granted on July 30, 2021 [Member] | Consultant [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Risk free rate	0.38%
Expected dividends	0.00%
Expected forfeiture rate	0.00%
Expected volatility	131.33%
Option life, share options granted | Year	1.5
Unvested stock-based compensation expense	$ 7,826

Stock-based Compensation (Dis_2

Stock-based Compensation (Disclosure of number and weighted average exercise prices of share options) (Details)	12 Months Ended
	Jan. 31, 2022Share$ / shares	Jan. 31, 2021Share$ / shares
Disclosure Of Share Based Compensation [Abstract]
Number of options outstanding, beginning of period | Share	9,095,000	350,000
Number of options, granted | Share	750,000	10,450,000
Number of options, expired | Share	(4,776,250)	(250,000)
Number of options, exercised | Share	(3,968,750)	(1,455,000)
Number of options outstanding, end of period | Share	1,100,000	9,095,000
Weighted average exercise price outstanding, beginning of period | $ / shares	$ 0.18	$ 0.1
Weighted average exercise price, granted | $ / shares	0.32	0.18
Weighted average exercise price, expired | $ / shares	0.17	0.1
Weighted average exercise price, exercised | $ / shares	0.15	0.15
Weighted average exercise price outstanding, end of period | $ / shares	$ 0.42	$ 0.18

Stock-based Compensation (Dis_3

Stock-based Compensation (Disclosure of number and weighted average remaining contractual life of outstanding share options) (Details)	12 Months Ended
	Jan. 31, 2022Share$ / shares	Jan. 31, 2021Share	Jan. 31, 2020Share
Disclosure of terms and conditions of share-based payment arrangement [line items]
Outstanding	1,100,000	9,095,000	350,000
Exercisable	780,000
Exercise Price | $ / shares	$ 0.42
Remaining Life (Years)	10 months 9 days
July 17, 2025 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Outstanding	80,000
Exercisable	80,000
Exercise Price | $ / shares	$ 1.02
Remaining Life (Years)	3 years 5 months 15 days
Expiry Date	July 17, 2025
March 10, 2022 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Outstanding	70,000
Exercisable	0
Exercise Price | $ / shares	$ 0.54
Remaining Life (Years)	1 month 9 days
Expiry Date	March 10, 2022
March 30, 2022 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Outstanding	200,000
Exercisable	200,000
Exercise Price | $ / shares	$ 0.54
Remaining Life (Years)	2 months 1 day
Expiry Date	March 30, 2022
March 23, 2022 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Outstanding	250,000
Exercisable	187,500
Exercise Price | $ / shares	$ 0.36
Remaining Life (Years)	1 month 24 days
Expiry Date	March 23, 2022
December 9, 2022 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Outstanding	250,000
Exercisable	125,000
Exercise Price | $ / shares	$ 0.35
Remaining Life (Years)	10 months 9 days
Expiry Date	December 9, 2022
July 30, 2023 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Outstanding	250,000
Exercisable	125,000
Exercise Price | $ / shares	$ 0.25
Remaining Life (Years)	1 year 6 months
Expiry Date	July 30, 2023

Capital Stock (Narrative) (Deta

Capital Stock (Narrative) (Details)	1 Months Ended	12 Months Ended
	Jul. 21, 2020shares	Jan. 31, 2022CAD ($)Share$ / sharesshares	Jan. 31, 2021CAD ($)Share$ / sharesshares	Jan. 31, 2020shares
Disclosure of classes of share capital [line items]
Number of shares issued | shares		109,051,292
Number of shares outstanding | shares		109,051,292	101,717,973	104,054,149
Number of units issued | shares		3,114,569
Units issued price per unit | $ / shares		$ 0.35
Proceeds from issuance of units		$ 1,090,085	$ 0
Exercise price of warrants exercisable | $ / shares		$ 0.5
Term of warrants		24 months
Expected dividend yield of warrants granted		0.00%
Risk free interest rate, warrants granted		0.29%
Expected volatility of warrans granted		131.00%
Expected life of warrants granted		2 years
Fair value of warrants issued		$ 394,681
Fair value of common shares issued		695,404
Share issue related cost		$ 3,770
Number of share options exercised | Share		3,968,750	1,455,000
Exercise price of share options exercised | $ / shares		$ 0.15	$ 0.15
Proceeds from exercise of options		$ 595,313	$ 213,250
Shares issued for consulting services (Shares) | shares		250,000	58,824
Fair value of shares issued for services		$ 36,250
Exercise of options		595,313	$ 213,250
Number of warrants exercised | Share			100,000
Weighted average exercise price of warrants exercised | $ / shares			$ 0.5
Proceeds from exercise of warrants		0	$ 50,000
Exercise of warrants			$ 50,000
Shares issued, price per share | $ / shares			$ 0.34
Consideration from shares issued			$ 20,000
Consideration from shares issued expensed to consulting services			8,333
Consideration from shares issued included in prepaid expenses			11,667
Share-based payment reserve [Member]
Disclosure of classes of share capital [line items]
Exercise of options		$ (361,284)	(108,435)
Warrant reserve [Member]
Disclosure of classes of share capital [line items]
Exercise of warrants			$ (7,481)
Cultivar JA Limited [Member]
Disclosure of classes of share capital [line items]
Number of common shares cancelled | shares			4,000,000
Option Exercise One [Member]
Disclosure of classes of share capital [line items]
Number of share options exercised | Share			1,355,000
Exercise price of share options exercised | $ / shares			$ 0.15
Option Exercise Two [Member]
Disclosure of classes of share capital [line items]
Number of share options exercised | Share			100,000
Exercise price of share options exercised | $ / shares			$ 0.1
MobileWellbeing ("MWB") [Member]
Disclosure of classes of share capital [line items]
Shares issued to acquire intangible assets, including closing | shares	50,000		50,000

Capital Stock (Disclosure of co

Capital Stock (Disclosure of continuity of warrants) (Details)	12 Months Ended
	Jan. 31, 2022Share$ / shares	Jan. 31, 2021Share$ / shares
Disclosure of classes of share capital [abstract]
Number of warrants outstanding at beginning of period | Share	1,548,000	1,648,000
Number of warrants exercised | Share		(100,000)
Number of warrants issued | Share	3,114,569
Number of warrants expired | Share	(1,548,000)
Number of warrants outstanding at end of period | Share	3,114,569	1,548,000
Weighted average exercise price at beginning of period | $ / shares	$ 0.5	$ 0.5
Weighted average exercise price exercised | $ / shares		0.5
Weighted average exercise price issued | $ / shares	0.5
Weighted average exercise price expired | $ / shares	0.5
Weighted average exercise price at ending of period | $ / shares	$ 0.5	$ 0.5

Capital Stock (Disclosure of nu

Capital Stock (Disclosure of number, exercise price and remaining life of outstanding warrants) (Details)	12 Months Ended
	Jan. 31, 2022Share$ / shares	Jan. 31, 2021Share$ / shares	Jan. 31, 2020Share$ / shares
Disclosure of classes of share capital [abstract]
Warrants Outstanding | Share	3,114,569	1,548,000	1,648,000
Exercise Price | $ / shares	$ 0.5	$ 0.5	$ 0.5
Remaining Life (Years)	1 year 1 month 2 days
Expiry Date	Mar. 5, 2023

Related Party Transactions (Nar

Related Party Transactions (Narrative) (Details) - CAD ($)	12 Months Ended
	Jan. 31, 2022	Jan. 31, 2021
Disclosure of transactions between related parties [line items]
Marketing expenses	$ 508,609	$ 221,670
Due to related parties	0	0
CEO [Member]
Disclosure of transactions between related parties [line items]
Marketing expenses	127,000	61,329
Advanced to CEO	$ 12,995	$ 12,995

Related Party Transactions (Dis

Related Party Transactions (Disclosure of transactions with key management personnel ) (Details) - CAD ($)	12 Months Ended
	Jan. 31, 2022	Jan. 31, 2021
Disclosure of transactions between related parties [line items]
Management fees	$ 269,845	$ 217,050
Rent	32,147	21,500
Key management personnel compensation	334,345	261,050
CEO [Member]
Disclosure of transactions between related parties [line items]
Management fees	109,500	99,500
Vehicle expense	18,000	12,000
Rent	28,500	21,500
A prior director [Member]
Disclosure of transactions between related parties [line items]
Management fees	0	6,000
COO [Member]
Disclosure of transactions between related parties [line items]
Management fees	92,000	68,000
Vehicle expense	18,000	10,500
CFO [Member]
Disclosure of transactions between related parties [line items]
Management fees	$ 68,345	$ 43,550

Commitments and Contingencies (

Commitments and Contingencies (Narrative) (Details)	Jul. 31, 2020CAD ($)
CEO [Member]
Disclosure of transactions between related parties [line items]
Monthly compensation	$ 8,500
Revised monthly compensation	10,000
Monthly rent obligation	2,000
Personal vehicle obligation	1,500
COO [Member]
Disclosure of transactions between related parties [line items]
Monthly compensation	6,000
Revised monthly compensation	8,500
Personal vehicle obligation	$ 1,500

Financial Instruments (Narrativ

Financial Instruments (Narrative) (Details) - CAD ($)	12 Months Ended
	Jan. 31, 2022	Jan. 31, 2021
Disclosure of detailed information about financial instruments [line items]
Cash and cash equivalents	$ 211,302	$ 480,051
Credit risk [Member] | One customer [Member]
Disclosure of detailed information about financial instruments [line items]
Percentage of revenue	100.00%
Percentage of accounts receivable	100.00%
Liquidity risk [Member]
Disclosure of detailed information about financial instruments [line items]
Cash and cash equivalents	$ 211,302
Current liabilities	$ 349,672

Capital Management (Narrative)

Capital Management (Narrative) (Details) - CAD ($)	Jan. 31, 2022	Jan. 31, 2021	Jan. 31, 2020
Disclosure Of Capital Management [Abstract]
Shareholders' equity	$ 886,985	$ 868,289	$ 1,583,656

Business Segment and Concentr_2

Business Segment and Concentration (Narrative) (Details) - CAD ($)	12 Months Ended
	Jan. 31, 2022	Jan. 31, 2021
Disclosure of operating segments [line items]
Property and equipment	$ 76,255	$ 8,188
India [Member]
Disclosure of operating segments [line items]
Property and equipment	$ 76,255
Credit risk [Member] | One customer [Member]
Disclosure of operating segments [line items]
Percentage of revenue	100.00%
Percentage of accounts receivable	100.00%

Income Taxes - Disclosure of de

Income Taxes - Disclosure of detailed information about effective income tax expense (recovery) (Details) - CAD ($)	12 Months Ended
	Jan. 31, 2022	Jan. 31, 2021
Major components of tax expense (income) [abstract]
Loss for the period	$ (1,882,178)	$ (1,584,533)
Tax rate	27.00%	27.00%
Expected income tax recoverable at statutory rate	$ (508,000)	$ (428,000)
Change due to acquisition, tax rates, and other	0	(32,131)
Non-deductible items	54,000	166,000
Share issuance costs	(1,000)	(26,000)
Expired non-capital losses	0	350,282
Change in unrecognized deductible temporary differences	455,000	(30,151)
Total income tax recovery	$ 0	$ 0

Income Taxes - Disclosure of _2

Income Taxes - Disclosure of detailed information about deferred tax assets (Details) - CAD ($)	Jan. 31, 2022	Jan. 31, 2021
Disclosure Of Information About Income Taxes [Line Items]
Total deferred tax assets	$ 1,856,000	$ 1,401,000
Less: Unrecognized deferred tax assets	(1,856,000)	(1,401,000)
Net deferred tax assets	0	0
Non-capital losses available for future period [Member]
Disclosure Of Information About Income Taxes [Line Items]
Total deferred tax assets	1,821,000	1,381,000
Share issuance costs [Member]
Disclosure Of Information About Income Taxes [Line Items]
Total deferred tax assets	13,000	19,000
Property equipment and intangible assets [Member]
Disclosure Of Information About Income Taxes [Line Items]
Total deferred tax assets	$ 22,000	$ 1,000

Income Taxes - Disclosure of _3

Income Taxes - Disclosure of detailed information about unrecognized temporary differences and tax losses (Details) - CAD ($)	12 Months Ended
	Jan. 31, 2022	Jan. 31, 2021
Non-capital losses
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Temporary differences	$ 6,745,000	$ 5,116,666
Temporary differences, expiry period	2027 - 2042	2027 - 2042
Share issuance costs [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Temporary differences	$ 47,000	$ 69,003
Temporary differences, expiry period	2042 - 2046	2042 - 2046
Property equipment and intangible assets [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Temporary differences	$ 84,000	$ 5,180
Temporary differences, expiry period	No expiry	No expiry